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Abstract
Botulinum neurotoxins are the most potent toxins known and are produced by 
the anaerobic bacteria of the genus Clostridium. These toxins are the 
causative agent of botulism (in human, animals, and birds), a neuroparalytic 
illness. Despite their potent toxicity botulinum neurotoxins are used in 
therapeutics and cosmetics. There exist seven antigenically distinct serotypes 
of botulinum neurotoxins (A-G). All botulinum neurotoxins have a similar 
domain arrangement - catalytic domain, transmembrane domain, and cell- 
binding domain. The toxin is non-toxic in the absence of cell-binding domain 
and such non-toxic fragments were highly researched for use in therapeutics. 
Structural characterisation of the non-toxic fragments would help in 
harnessing their effect as a effective pharmaceutics. Crystallisation studies 
and successes on the non-toxic fragments of botulinum neurotoxins and their 
first X-ray diffraction data are reported.
The entry of botulinum neurotoxin toxin into the host neurons is still not 
completely understood. Botulinum neurotoxins are thought to be internalised 
by receptor-mediated endocytosis after the toxins bind to the neuronal cell 
surface. Here we report the crystallisation trials and structural studies to 
obtain botulinum neurotoxin B in complex with its receptor synaptotagmin II.
Erythrina cristagalli lectin (ECL) is a carbohydrate binding protein specific for 
galactose and A/-acetyl galactosamine and is a biological dimer. ECL in 
conjugate with botulinum neurotoxins non-toxic fragments was used to 
retarget cells as a therapeutic in the treatment of chronic pain. Understanding 
the structural mechanism of ECL will aid in using it as a drug delivery vehicle. 
It is thought that the dimer formation between two monomers is mediated by 
A/-linked glycosylation (‘hand-shake’ model). But, our recent study and results 
tells that the A/-glycosylation is independent of the dimer formation indicating 
that the functional properties of ECL are dictated at its primary sequence 
itself.
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Ribonucelases are enzymes that catalyse the cleavage of phosphodiester 
bonds in RNA. Bovine pancreatic ribonuclease A (RNase A) and its 
homologues possess different properties and functions like angiogenesis 
(angiogenin), anti-viral and anti-bacterial (eosinophil-cationic protein (ECP) 
and eosinophil derived neurotoxin (EDN)) properties in living systems. An 
effective inhibitor of angiogenesis could inhibit the formation of new blood 
vessels in tumour cells, and inhibitors for ECP and EDN could be used to 
regulate the eosinophilic content of these proteins during inflammation 
processes. Here we report the biochemical and structural studies on binding 
of four different inhibitors to RNase A.
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Living forms are classified as Viruses, Prokaryotes and Eukaryotes (Appendix 
I). The building blocks of all living forms are cells except viruses, which are 
made up of RNA (ribonucleic acid) protected by protein core. The functional 
units of cells are proteins (Appendix I), which are polymers of amino acids. 
Proteins play a very important role as transporters, catalysts, regulators, 
sensors, and in host defence. The function of a protein is defined by its 
structure as dictated by its sequence. Hence, structural characterisation of 
proteins is very important to understand the chemical nature of the protein 
and the mechanism of its function in a living cell. There are many methods 
available to determine the tertiary or three-dimensional structures of proteins, 
experimental methods include X-ray crystallography, Nuclear Magnetic 
Resonance spectroscopy (NMR), Electron microscopy, Neutron scattering, 
and y-ray resonance scattering.
Bioinformatics or computational biology applies the knowledge gained from 
the experimental studies to predict the tertiary structure of the protein from its 
primary sequence. This method of predicting three-dimensional structures of 
proteins is called homology modelling. The principle is that sequence 
determines the structure of a protein. Hence, more similar sequence should 
have a similar structure, which is the basic criterion for homology modelling. 
Yet, homology models are only models and are biased on the template used 
and cannot define the nature of arrangement or conformation of the protein 
molecules as defined by the experimental methods.
1.1 X-ray Crystallography
X-ray crystallography is the most superior of all techniques known today to 
determine the three dimensional structures of macromolecules. 
Macromolecular crystallography has become an integral and important part of 
modern biology. It finds its use not only in structure determination of
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molecules, but also guide efforts to chemically modify (Appendix I) the 
molecules to aid in understanding their functional/biological role in an 
organism.
After the discovery and report by W. C. Rontgen in 1895, that X-rays can 
affect a photographic plate and failed to possess wave nature i.e. X-rays are 
highly penetrating radiations and do not obey laws of reflection, refraction 
and/or diffraction, it was Max von Laue in 1912, first to beam the X-rays on to 
a Zinc sulphide crystal placed between the X-ray source and the photographic 
film. He observed a diffraction pattern on the photographic film similar to the 
interference phenomenon of light from an optical grating element. This pattern 
contained a regular array of spots, which were later called as Laue Spots. 
This phenomenon supported that X-radiations possess wave property and 
diffracts in the wavelength range of 0.1 A -  100 A.
Vonocnromatic 
X rays
Fig 1.1 A schematic representation of Laue spots.
1.2 Bragg’s Law (Bragg 1913a; Bragg 1913b)
W. L. Bragg noticed the similarity of diffraction to ordinary reflection and 




Fig 1.2 Bragg’s law
Let l i and Ri, I2 and R2 be the incident and reflected (diffracted) X-rays (of 
wavelength A) from the planes P1 and P2 respectively. Planes P1 and P2 are 
separated by a distance d. The incident and the reflected beam are inclined at 
an angle 0 to the planes P1 and P2. According to the law of diffraction, for a 
two waves to be in phase the path difference must be an integral multiple of 
the wavelength. Thus, AC+CB the path difference between /*, R1 and I2 , R2 
should be an integral multiple of wavelength for the two waves to travel in 
phase.
AC+CB = 2AC = nA 
AC = d sinO 
Thus, nA = 2d sinO —  Bragg’s law.
The unit of wavelength A is A and 1A=1x10"8 cm
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1.3 Crystal System and Symmetry
A crystal can be defined as a highly ordered big block containing a uniform 
array of the atomic motif repeating in three-dimensional space.
cell
Fig 1.3 Diagramatic representation of unit cells in a crystal.
Crystals exist in different forms (Table 1.1). Based on their type and property 
they are divided and grouped under a common crystal class or system. The 
seven types of crystal systems given in the Table 1.1 are in the increasing 
order of symmetry based on the number of independent parameters. The 
lengths of the unit cell edges are designated as a, b and c and the angle 
between the axes b and c is a, a and c is /3, a and b is y (Fig 1.3). In addition 
to these seven primitive lattices Bravais discovered another seven non­
primitive lattices. These seven primitive lattices and seven non-primitive 
lattices are together called Bravais lattices. Primitive lattices are those crystal 
systems that contain one point at each corner of the unit cell and are 
designated by letter P. Non-primitive lattices have points in the center of the 
unit cell faces or unit cell itself in addition to the points at the corner of the unit 
cell and are classified as face centered (A, B, C, and F), and body centered
(I).
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Table 1.1 Seven crystal systems of Primitive lattices.
Crystal system Number of degrees of 
freedom
Parameters
Triclinic 6 a^b^c; a^p^y
Monoclinic 4 a*b*c; a=Y=90°; (B > 90°
Orthorhombic 3 a^b^c; a=p=Y=90°
Tetragonal 2 a=b^c; a=p=Y=90°
Trigonal
Rhombohedral lattice 2 a=b=c; a=p=Y^90°
Hexagonal lattice 2 a=b=c; a=p=90°; y=120°
Hexagonal 2 a=b=c; a=p=90°; y=120°
Cubic 1 a=b=c; a=p=Y=90°
1.3.1 Point Groups
This is a symmetry group operation that can be used to define the symmetry 
(arrangement of atom or molecule) of a crystal using the symmetry operators 
like rotation, mirror plane, inversion and center of symmetry. There exist 32 
point groups.
1.3.2 Space Groups
Space group operation is a representation (arrangement of atom or molecule) 
of a three dimensional crystal, using all symmetry elements including glide 
planes and translations present in the crystal. 230 unique space groups (listed 
in International Tables of Crystallgraphy, Volume A (Hanhn et al. 1987)) are 
derived from 32 point groups and 14 Bravais lattices.
15
1.4 Protein Structure Determination by X-ray Crystallography
Structure remains the ultimate answer to define and describe the functions of 
proteins or enzymes and their chemical nature. The events in the 
determination of 3D-structure by X-ray crystallography are shown as a 
flowchart in Fig 1.4.
 T
Identifying the Gene of interest
*
on and Purification of the Prot
ilisation of the Prot
1
X-ray Data Collection 





Phase ($) determination by any of the 
following methods:
SIR, MIR, SAD, MAD, SIRAS, MIRAS, 
Direct Methods, Integrated Direct Methods
Model Building and Refinement 
rotation of Electron Density Map witl
4
jre Analysis and Val
Structure Submission to Protein Data Bank
Fig 1.4 A flowchart representation of typical steps in molecular structure 
determination by X-rays.
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The pre-requisite for X-ray crystallographic diffraction studies is to have the 
crystals of the protein of interest. Proteins can either be obtained from the 
native/natural source if possible or over expressed in different systems 
depending on their availability and ease of production. Pure protein is then 
screened for crystallisation trials, which will be further used for diffraction 
studies. In cases where obtaining pure protein from wild source is rather 
difficult or the protein is from mammalian ceils, the target protein is expressed 
in a foreign host where one has many choice of selection.
1.4.1 Protein Expression
Protein expression in vitro is the choice of most researchers to obtain the 
protein of interest in large quantities. The important criteria for in vitro 
expression in selection of host are:
- The protein of interest is non-toxic or harmless to the foreign host.
- Protein is expressed in soluble form. Few cases where expression 
is in insoluble form (aggregates) selection of different fusion 
protein/tags or a different host should be considered.
- In case of poor expression one can consider different bacterial 
strains and also different expression vector system.
- Preferably as a non-interacting species to any other protein in the 
host.
- Capabilities of the host to over express the protein of interest.
- Should undergo post-translational modifications (as required for 
structural studies) as in the native source to become a fully mature 
product.
Several systems such as bacteria, insect cells, drosophila cell lines 
(Yamaguchi et al. 1965; Winslow et al. 1989; Wang et al. 1993; Torfs et al.
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2000), yeast (van den Berg et al. 1990; Fleer et al. 1991; Rocha et al. 1996; 
Tokunaga et al. 1997; Walsh and Bergquist 1997; Walsh et al. 1998), 
mammalian cells (Laemmli 1970; Graham and van der Eb 1973; Wigler et al. 
1977; Xu and Beckett 1994), and cell-free systems can be a choice of host 
selection to be used for the production of target protein using the recombinant 
method. Escherichia coli is the most commonly used in vitro expression 
system for most of the proteins. The advantage of use of E.coli in expressing 
the recombinant protein is that the whole genome information about E.coli is 
well studied and characterized and the bacterium has a high growth rate 
compared to any other systems. In cases where posttranslational modification 
of the target protein is not achieved in conventional bacterial expression 
system like E.coli, yeast or eukaryotic cell lines are the other choices of 
selection to express the protein of interest. The next step is to purify the over 
expressed protein using any of the available protein purification methods.
1.4.2 Protein Purification
Protein purification, whether from native source or by recombinant method is 
a challenging task. Protein purification can be single-step purification, but 
most of the time requires more than one step to obtain the final pure product. 
Protein purification normally involves chromatographic techniques and many 
different chromatographic methods are available. One needs to be selective in 
the chromatographic method used or in the combination of different 
chromatographic techniques for purification of any protein. There is always 
some loss of protein of interest in each purification step, so one has to be 
selective and limit the number of steps involved in purification but not at the 
cost of purity. This could be achieved by expressing the target protein along 
with affinity fusion tags/proteins such as Glutathione S-Transferase (GST) 
(Smith and Johnson 1988), po/yHis (Studier and Moffatt 1986; Rosenberg et 
al. 1987; Studier et al. 1990), Maltose Binding Protein (MBP) (di Guan et al. 
1988; Maina et al. 1988), Calmodulin (Aslanidis and de Jong 1990), 
Biotinylated fusion tags (Samols et al. 1988; Cronan 1990; Wilson et al. 1992;
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Xu and Beckett 1994), Intein-Mediated Purification with an Affinity Chitin- 
binding Tag (IMPACT) (Xu et al. 1993; Chong et al. 1996; Xu and Perler 
1996; Chong et al. 1997; Chong et al. 1998a; Chong et al. 1998b), 
polyHis*Strep (Schmidt et al. 1996; Skerra and Schmidt 2000; Smyth et al. 
2000)etc. Commonly used chromatographic techniques are Affinity 
chromatography, Ion-exchange chromatography, and Size-exclusion 
chromatography.
Affinity chromatography such as Ni-NTA exploits the principle that the target 
protein binds/chelates reversibly to the Ni-NTA charged column and eluted 
with different concentration of another ligand (usually imidazole) that possess 
higher affinity to the protein. Ion-exchange column chromatography separates 
proteins based on the charge carried by the protein. In this method all proteins 
including impurities that are bound to the ion-exchange column are separated 
by a salt gradient elution. Size-exclusion chromatography separates the 
proteins according to the molecular weight of the protein. Typically size- 
exclusion chromatographic technique is the final polishing method applied to 
get the purest sample. An SDS-PAGE is run after each chromatographic 
technique used or after each step used in the protein purification processes to 
ensure that the protein purified is pure. Biophysical (Circular Dichroism (CD) 
and Mass spectrometry) and biochemical characterisation should be carried 
out to confirm that the protein purified is fully mature and functionally active.
1.4.3 Protein Crystallisation
Crystallogenesis is a process of growing proteins as crystals. Almost all 
proteins are very selective about the chemicals and reagents used to aid them 
in crystallogenesis. There are two important phases in the process of crystal 
growth - nucleation and growth. Nucleation is a process of aggregation of 
similar molecules in the crystallisation medium, which results in
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supersaturation of the protein molecules followed by growth phase. In the 
growth phase the crystal grows in three-dimensions. Depending on the 
polarity and arrangement of the protein molecules the crystals grown will be of 
different shape. Macromolecular crystals are not solid crystals but are 
intermediate between fluid and solid and are called crystalline solids. Protein 
crystals have solvent channels in between neighbouring molecules of the 
crystal.
Crystals can be grown by many different methods like Hanging drop method, 
Sitting drop method, Batch method, Sandwich method, Dialysis button 
method, Gel and Microbatch method. Many factors that influence the crystal 
growth are purity of the sample, pH, salt, temperature, stability, etc. The 







Fig 1.5 Phase diagram of crystallisation process
Hanging drop method: The most commonly used method to grow protein 
crystals is by the hanging drop technique (Fig 1.6). One of the main 
advantages of this method is that it requires less protein than any other 
methods. A few micro litre of protein solution is mixed with an equal amount 
(usually 1:1) of reservoir solution containing the mother liquor and placed as a 
drop on the cover slip. Crystallisation is achieved by supersaturation. A thin 
layer of grease seals the cover slip on the well containing the mother liquor. 





'  with Protein
Fig 1.6 Hanging drop method.
1.5 X-ray Diffraction Data Collection
Any crystals grown should be exposed to X-rays to record the diffraction 
pattern, which provides the source of data for structure solution. The X-ray 
diffraction data collection depends on the choice of the crystal and the 
wavelength of the X-ray used.
1.5.1 Choice of Crystals for X-ray Diffraction Studies
The diffracting property of a crystal depends solely on the quality of the crystal 
grown. Not necessarily all crystals grown under the same condition and/or in 
the same drop will exhibit the same quality of diffraction. Hence, choice of 
crystal selection is important in diffraction data collection. One cannot come to 
a conclusion about the choice of a crystal by the look of it. Salts in the mother 
liquor might get crystallised instead of protein and it is very difficult to 
characterise them under the microscope. The only way to check the crystal 
quality is to shoot them with X-ray beam and record the diffraction strength. 
Some crystals might diffract strongly, some weakly, and others fail to exhibit 
diffraction. Salt crystals can be easily differentiated from protein crystals by 
looking at their diffraction pattern.
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1.5.2 X-ray Sources and Detectors
X-rays are produced by bombarding high velocity electrons on to a metal 
target. X-radiation lies in the region between the ultraviolet rays and gamma 
rays in the electromagnetic spectrum and is of the order of wavelengths 0.1 A 
-  100 A. A commonly used metal in the production of X-rays is Copper for its 
advantage in efficient recording of the diffraction data and suffers less 
absorption while passing through the medium or air. Other metals used are 
Molybdenum, Chromium, Iron, etc. For a long time in-house X-ray sources 
have been used to generate X-rays (eg. a rotating anode). However, the 
intensity of the emitted beam is very low as it is directly proportional to the 
number of electrons emitted at any given time and the images have to be 
recorded for a very long time. Synchrotron Radiation Sources (SRS) are 
routinely used for X-ray diffraction data collection and the X-rays produced are 
of more intense than the in-house source and the diffraction measurement 
requires less time.
Use of synchrotrons in X-ray diffraction studies has several advantages of 
which reduction in the duration of data collection from days to hours is one of 
the important factors. X-radiation generated at synchrotrons is of very high 
intensity and greater magnitude of about 2 GeV. The SRS offers a wide range 
of wavelengths for different experiments extending from the infrared to hard 
X-rays to different techniques including X-ray diffraction, X-ray spectroscopy, 
small-angle/wide-angle scattering, soft X-ray spectroscopy, photoemission, 
imaging, nanoscience, time-resolved X-ray spectroscopy, etc. In synchrotrons 
the electrons are amplified in a booster and are fed into the high-energy 
storage ring where the electrons travel at relativistic speeds of light and gain 
high momentum. The X-ray diffraction experiments are carried out in a hutch 
positioned tangential to the storage ring where the circulating electron beam is 
released from the high-magnetic field. Charge Coupled Device (CCD) 
detectors are superior to image plates as they have a very good spatial 
resolution, good noise reduction, and shorter read-out time. CCD detectors 
are now commonly used in in-house source and in SRS.
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1.5.3 X-ray Data Collection
The next step in structure solution is X-ray diffraction data collection. 
Diffractrometers are instruments used to collect X-ray diffraction data. The X- 
rays are beamed on to the crystal mounted on the goniometer. The 
goniometer is a part of the diffractometer where the crystal is mounted and 
positioned in space to be in the center of the X-ray beam. There are many 
parameters such as distance between the crystal and detector, crystal 
oscillation range (A</>) of the crystal about rotation <|>-axis, the number of 
images to collect to get a complete dataset, and exposure time that one 
should consider for data collection. The diffraction range depends on the 
crystal to detector distance following Bragg’s equation
d = X/{2 sin 0)
The major difficulties in intensity measurements that arise are: (a) The 
scattering of radiation other than Bragg reflection, (b) The intensity of the 
beam, (c) The boundaries of the reflection must be correctly defined 
irrespective of the spot size, shape and intensity, (d) The diffraction spots are 
always accompanied by other scattered radiation, called as background, 
which must be adjusted while data processing. This might be due to diffuse 
scattering of X-rays of all wavelengths by all objects in the beam, including air 
and crystal.
The molecular information that one can obtain from X-ray diffraction data is 
solely dependent on the resolution (wavelength XA) of X-radiation used.
The concept of Resolution
Resolution is defined as the distinct interpretation of two closely spaced spots 
(atoms by X-rays) on the diffraction image. Thus, the details of the structure is 
proportional to the resolution used (Blundell and Johnson 1976; Acharya and 
Rees 1995). In terms of X-rays resolution is defined as the wavelength A of 
the incident beam. The information in Table1.2 gives an idea about what one 
might expect at the given resolution.
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Table 1.2 Details of structure one might expect at given resolution.
Resolution
(A)
Details of the structure
6.0 Outline of the molecule, secondary structural features 
(helices, beta strands) can be identified.
3.0 Course of the polypeptide chain can be traced and 
topology of the folding can be established. With the aid of 
amino acid sequence, it is possible to place the side 
chains within the electron density map.
2.0 Main chain conformations can be established with great 
accuracy. Details of side chains, some bound water 
molecules, ligand, and metal ions can be identified.
1.5 Individual atoms are almost resolved. It is possible to 
assign large part of the solvent structure.
1.0 Hydrogen atoms may become visible. Multiple 
conformations for some of the side-chains can also be 
seen.
The concept of Reciprocal Lattice and Ewald Construction 
From Bragg’s law
sin 0 = (nM2)*(1/d)
sin 6 is directly proportional to 1/d, the interplanar spacing in the crystal 
lattice. When crystals diffract X-rays, closer diffraction pattern is observed for 
lattices with larger d in real space and wider diffraction pattern for lattices with 
smaller d. Thus, the diffraction patterns observed are in reciprocal space
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(1/d). Not all the points on the lattices contribute to any observed diffraction at 
a time. Only those lattice points that lie within the limiting sphere contribute to 
the diffraction. Limiting sphere is a sphere in three-dimensions constructed 
with radius 1/A. All lattice points that fall on the circumference/on the surface 
of the limiting sphere diffract X-rays. This construction is called Ewald sphere 
(Fig 1.7). The crystal is rotated about its rotation g>-ax\s and the diffraction 
data are collected. Irrespective of the degree of rotation the lattice spacing 
remains the same throughout during the process of X-ray diffraction data 
collection.
Consider a circle (Fig 1.7) with centre C and radius AC = 1/A, where A is any 
point on the circumference of the circle where the incident beam I meets. O is 
the direct emerging beam and is collinear with the incident beam I. As per 
Ewald’s construction all points that lie on the circumference of the sphere of 
reflection contribute to diffraction phenomenon. D, E, F, G, and FI are the 
points from different and/or same lattice planes of the crystal C that lie on the 
circumference of the limiting sphere. Ri, R2, R3, R4 , and R5 are the reflected 
beams when Bragg’s law is obeyed.
Fig 1.7 Ewald construction
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Radiation damage
Radiation damage to the crystal in X-ray beam is an unavoidable situation 
during the process of X-ray diffraction data collection. This arises due to 
several factors such as evaporation of solvent molecules in the crystal, and 
heat produced by the incident X-ray beam (quantum effect). Radiation 
damage leads to disorderness of the crystal lattice resulting in low-resolution 
diffraction data and/or loss of resolution and diffraction. This problem can be 
overcome to certain extent by collecting the data at cryo temperatures 
(usually at 100K), where a stream of nitrogen gas is focussed on the mounted 
crystal. Cryo temperatures could freeze solvent molecules in the crystal 
leading to ice formation on the crystal resulting in poor quality diffraction data. 
The process of ice formation at cryo temperatures could be successfully 
avoided by soaking the crystal in cryo protectants (glycerol, MPD, etc.) prior to 
data collection.
1.6 Data Processing, Data Reduction and Scaling
The raw data from X-ray diffraction data collection or Intensity data collection 
contains all information about the crystal, symmetry and the structure of 
molecules in terms of observed intensities only. One need to know the 
position of atoms/molecules called as phase in order to define the structure, 
which is discussed later in the section ‘Phase problem’. Firstly, one has to 
extract all information from the raw data by carefully examining the diffraction 
images. Secondly, the obtained information is to be scaled to contain unique 
set of reflections that will define the molecule.
1.6.1 Data Indexing and Processing, and Integration of the Raw Images
All the observed intensities (spots) on a diffraction image must be defined a 
position with reference to other observed intensities. This process of defining
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all the spots a defined position is called indexing, which is the first step in X- 
ray diffraction data processing. All cell dimensions like the axes lengths, 
angles are calculated and the possible lattice type (space group) is selected 
using the conditions in the Table 1.1. For a long time scientists were doing the 
indexing with their eyes with the help of simple devices to measure the 
intensities, cell dimensions, etc. Development in detectors, computational 
crystallography and automation has given rise to new software suites, which 
are capable of indexing the images automatically (Otwinowski and Minor 
1997a). The indexed images are to be refined for the defined positions for the 
unique space group. This step is very important as it gives information about 
the choice of selection of space group. There are many parameters one has 
to take into account while the process of indexing and processing like intensity 
spot radius, the background of the spots -  very important to define the 
boundary of each spots in order to avoid the overlap of neighbouring spots, 
the shape of the spots, and the spread of the spots in a diffraction image 
(mosaicity). Mosaicity is an important parameter, which defines the quality of 
the crystal and data collected. Greater mosaicity means the high degree of 
disorderness in the crystal lattice. One has to refine all the parameters 
carefully to get the most out of the diffraction images and to use all the data 
collected.
1.6.2 Data Reduction and Scaling
Data reduction and scaling is the final step in X-ray diffraction data 
processing. The 7?' number of images collected for a crystal by rotating about 
its rotation ^-axis contains partially observed reflection of the previous image 
and the following image. Also some of the observed reflections will be the 
same in a couple of images. This is because when the crystal is rotated the 
same lattice points will fall on the limiting sphere after a few degree of rotation 
and Bragg’s law is obeyed. This redundancy in the data should be reduced 
and scaled to a non-redundant dataset where all the sets of reflections after 
scaling are brought to a common scale and are unique and contain all the
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information about the crystal. Other statistical information obtained from 
scaling is an overall estimate of mean thermal motions/vibrations for the 
molecule in the crystal space.
1.7 Phase Problem
What we actually record during X-ray intensity data collection?
Is there any information lost during X-ray data collection and if, how can it be 
obtained?
When we know the symmetry, unit cell dimensions and unit cell volume what 
are the missing parameters that would define the position o f molecules in the 
unit cell?
These questions look simpler but involve lots of vector mathematics and 
statistics. The position of a molecule in space is defined by its direction and 
magnitude to a reference point. The crystallographically available data consist 
only of the structure factor magnitudes (|Fhki|) in the form of 
intensities/amplitudes and not their positions. This is called the phase 
problem. Thus one has to obtain the phase information lost during X-ray 
intensity data collection in an indirect way before reconstructing the three- 
dimensional image from the diffraction pattern.
By definition, structure factor is a vector quantity, which is the resultant of N 
waves scattered by the N atoms in the unit cell. Each of these waves has 
amplitude proportional to fj, the atomic scattering factor and contains the 
information about phases. Structure factor in simple exponential form is given 
by the formula,
r~ _  r-ir 27rih.X. 
hhkl -  2Aje J
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Wheire, Fhki => Structure factor of the atom
fj => atomic scattering factor of the /th atom 
hkl => iMiller indices
1.8 Methods to Determine Phases (cp)
There are many methods by which one can derive the phases (p) of the 
molecule.
1.3.1 Molecular Replacement Method
Molecular replacement method (Rosmann and Blow 1962; Rosmann 1990) is 
the first choice of all the structural biologists when there is a homologous 
structure available. Homology between the observed data and available 
structure is determined at the primary structure level. Successful calculation of 
approximate phases for an unknown structure from a known molecule, which 
shares homology greater than 20 % to the target sequence, has been 
achieved using this method. The principle is to find the relative orientation 
(rctalion) and position (translation) of the unknown in space by performing 
rotation and translation operations on the known phases irrespective of the 
space group of the known molecule. MOLREP (Vagin and Teplyakov 1997), 
AMORE (Navaza 1994), and Phaser (Storoni et al. 2004) are a few of the 
mostccmmonly used programs of this technique.
Patterson synthesis
Patterson function is applied or is integrated as a part of the molecular 
replacement method to find the orientation and position of the molecules in a 
unt cell. Patterson function is a vector representation of the observed 
intensities given by the equation
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P(uvw) = (1/V)Zj\F(hk!)\2 cos[2x(hu+kv+lw)]
where, uvw are Patterson coordinates
Note: The equation has got only the cosine term and not the sine term which 
tells that the |F|2 are phaseless quantities or phase equals zero degree.
Pattern synthesis thus produces a map of intra- and inter- atomic vectors. The 
intra-atomic vectors are self-vectors arising from the same molecule (vector 
distances will be smaller) and the inter-atomic vectors are cross-vectors 
arising between different molecules (vector distance will be larger) in a unit 
cell. For a molecule containing N atoms there will N(N-1) vectors/peaks in a 
Patterson map. Thus the relative orientation of the molecules is defined by the 
self-vectors while the position or translation is defined by the cross-vectors. 
Any Patterson function is centrosymmetric and the screw or translational 
symmetry are substituted with rotation and mirror plane symmetry. This is 
because for any pair of atoms in the molecule there are calculated vectors of 
opposite direction and same magnitude.
Steps in Molecular Replacement Method: (Fig 1.8)
1. Identification of the phase target (a target is the known structure) by 
sequence homology: Here one searches for any available structure in 
the Protein Data Bank with similarity (>20 %) in primary sequence.
2. Calculation of Patterson vectors using Patterson co-ordinates for the 
observed data (unknown) and the target (known).
3. Superposition of known and unknown: Involves two searches called 
rotation and translation.
unknown (cp) = R (known (<p)) + T
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where, R => Rotation function, T => Translation function
a. To find the orientation of the Patterson vectors of the known with 
respect to the unknown in the cell. This is called rotational 
search. In total there are three rotational axes.
b. Once the optimal orientation is found, the position in the cell 
must be found. This is called translational search. In total there 
are three translational vectors one for each rotational axes.
4. The best fit is found by calculating the agreement brought by 
superposition method and the phases are assigned to the unknown.
Fig 1.8 A diagramatic representation of Molecular Replacement Method. 






1.8.2 Isomorphous Replacement Method
Isomorphous replacement method (Green et al. 1954) exploits the principle 
that each atom in the molecule contributes independently to the scattering 
factor (amplitudes). A heavy atom (metal) bound to the molecule will 
contribute more to the scattering power than any other atoms in the molecule 
and is more prominently observed in the difference Patterson map. Two 
dataset, one for the native and the other for the derivative set (heavy atom 
soak) are collected and are called isomorphous when there is no observable 
difference in their lattice organisation after the introduction of a heavy atom. 
Concentration/selection of heavy atom should aim not to alter/drastically 
change the lattice properties of the crystal. If the introduction of heavy atom 
does not alter the rest of the structure called non-isomorphism, by 
constructing Harker sections, one can determine the phase ($  information of 
the molecule. Usually more than one isomorphous derivative can be a better 
choice in determining the phase of the molecule, thus reducing the phase 
ambiguity. Single Isomorphous Replacement (SIR) method (Blow and 
Rossman 1961) and Multiple Isomorphous Replacement (MIR) method are 
used to determine the phases by this method.
1.8.3 Anomalous Scattering Method
Anomalous scattering (resonance scattering) of atoms is observed when the 
wavelength of X-radiation used is close to the absorbance edge of the 
scattering atom present in the crystal. Application of anomalous scattering 
method is amenable at synchrotron sources where one can tune the 
wavelength close to the absorbance edge of the anomalous scatterers 
present. Phasing with the help of anomalous scatterers in the X-ray diffraction 
data (Hendrickson et al. 1985) is similar to isomorphous replacement method, 
but taking the advantage that the conditions at which the scattering factor 
differs with the dispersion. Under normal conditions when non-anomalous 
scatterers are present, the reflections obey Friedel’s law, i.e. Fhk r  F_h-k-i- In
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the presence of anomalous scatterers, the Friedel’s law is violated, thus Fhki 
*  F-h-k-i. Similar to SIR/MIR, anomalous scattering data collection can also be 
done using Single-wavelength Anomalous Dispersion (SAD) and Multiple- 
wavelength Anomalous Dispersion (MAD) techniques to determine the 
phases. However, the method has a drawback that the anomalous difference 
signal between dataset is sometimes too weak. The method can become 
more powerful when combined with isomorphous replacement technique and 
is called as Single wavelength Isomorphous Replacement and Anomalous 
Scattering (SIRAS) and Multiple wavelength Isomorphous replacement and 
Anomalous Scattering (MIRAS).
1.8.4 Direct Methods (DM) And Integrated Direct Methods
Direct Methods
Deriving phase relationships directly from the observed intensities to solve the 
phase problem is called Direct Methods. Phases are derived using symbolic 
addition methods. A few assumptions of direct methods are:
i) The structure factors are considered as normalized structure
factors by the equation
where, Eh => Normalised structure factor
Fh => Structure factor
fj => Atomic scattering factor
ii) The electron density is always positive.
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iii) Each atom is considered as point/unitary atoms.
Direct Methods are successfully applied to small molecules data to find 
phases. The usage of Direct Methods to solve protein structures is reported 
by Karle in 1989. One needs very high resolution data with high redundancy 
for a successful use of Direct Methods to obtain phases. Attempts to solve 
protein structure by ab initio method of using Direct Methods were successful 
for proteins with less than 3000 non-hydrogen atoms. However, Direct 
Methods when integrated with any of the well-known techniques of phase 
determination (Isomorphous replacement (Giacovazzo et al. 2001), 
Anomalous dispersion, Patterson search) can give better estimates of phases.
1.9 Phase Refinement and Model Building
The final agreement between the observed diffraction data and calculated 
phases is brought by a process called refinement.
What do we actually do in the process of refinement and what is refined 
against what?
These are a few questions addressed in this section.
1.9.1 Model Building using Fourier Maps
The structure factor Fhki is considered to be the sum of scattering of all the 
free electrons in a unit cell and contains the phase information of the 
molecule. Electron density is defined as the number of electrons per unit 
volume and is the Fourier transformation of structure factors given by the 
equation,
p(x,y,z) =  (1/V) Ehk,Fhk, e'2"h xj
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where, p(x,y,z) => electron density over the volume
element V
Once there available initial sets of phases for a fraction of the molecule the 
next step is to extend these phases (model building) with the knowledge of 
chemistry of the molecule. This is done with the help of electron density maps 
(Fourier maps). Different Fourier maps are calculated and used as a guide in 
model building. The rule of a thumb in calculating electron density maps is to 
use all the reflections measured, as the observed data is always true and will 
show up clearly in the electron density maps. Usually most of the model 
building is done with two kind of Fourier maps calculated:
Difference Fourier Maos: denoted as AF = Fo - Fc, where the observed data 
and calculated phases are given equal weights. The importance and beauty of 
difference Fourier map is that it will clearly show any wrong substitution made 
during the process of model building.
Double Difference Fourier Maos: the observed data is given double weight 
(2Fo) in calculating double difference Fourier maps (2Fo - Fc) to guide 
through the process of model building. Because when Fo = Fc, no electron 
density is observed. Thus, the observed data is given more weight and used 
along with AF during the process of model building.
Interpretation of electron density maps is a time consuming and laborious task 
in model building. Developments in computation and visualisation tools have 
provided crystallographers with graphics software suites/tools that enable 
them to do model building on a personal computer. Model building accounts 
for all observed data by knowing what is in the crystal or what was 
crystallised, like protein atoms, solvent atoms, metal ions, and 
ligands/substrates if any present. At each stage of model building electron 
density maps are calculated and any difference observed is fitted into the 
density and taken into account for next round of refinement.
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1.9.2 Refinement of the Final Model
What do we refine and try to achieve during the process of refinement? 
Refinement is always followed by model building until,
• all the observed electron density is accounted for, i.e. addition of 
ligands and/or solvent atoms after accounting for all protein atoms. 
Addition of solvent atoms depends on the resolution of the data 
collected (Table 1.2).
• one finds closer agreement between the calculated (Fc) and observed 
(Fo) structure factors.
The calculated phases (Fc) are refined against the phases observed (Fo) 
during the process of refinement. There are several parameters that one has 
to take into account during the process of refinement of the model like the 
positional parameters (bond length, bond angle, torsion angle, and planarity) 
of the molecule, and temperature factor for each atom. This is done in two 
different ways strictly abiding the rules of chemistry, thus refinement can be 
either constrained or restrained.
In a constrained refinement the bond lengths (Appendix I), bond angles 
(Appendix I) are considered as rigid bodies whilst refining only the dihedral 
angles (Appendix I). By doing constrained one can reduce the number of 
parameters required for further refinement. In a restrained refinement the 
positional parameters are refined with reference to the energy. The variables 
are bond lengths, bond angles, torsion angles, thermal vibration factor (B- 
factor). Refinement comes to an end where there is no observable change in 
the reliability index called the R-factor after accounting for all the difference 
electron density observed.
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R-factor is given by the formula,
2 ^  i i f j  ■ m \
....................................x 100%
S m q  |f „I
where, k is the scale factor
h,k, and I are the reciprocal lattice points
value:
Overfitting the model by accounting for all the electron density observed could 
relatively bring down the R-factor. In 1992 Axel T. Brtinger (Brunger 1992;
1993) introduced a factor called free R factor in addition to R-factor, which is 
calculated in a similar way as the R-factor. Rfree includes a very small amount 
of reflections called test set, which is not included in the process of refinement 
along with calculated structure factors. This free R relates to the absolute 
phase error in the model and any overfitting of data or even unjustified 
addition of solvent molecules to the model data is accounted by increases 
free R-values.
1.9.3 Structure Validation and Submission
Structure validation is a process where fine-tuning of the refined structure is 
done. There are several tools available to validate the solved structure. 
Ramachandran plot (Fig 1.9) (a (p-tp plot for main chain atoms in a peptide 
plane) (Ramachandran et al. 1963) provided the first tool in validation to 
check the allowed and disallowed conformations present in the observed 
structure. Statistics states that more than 85% of the total residues should be 
in the allowed region of the Ramachandran plot. PROCHECK (Laskowski et 
al. 1993) is used to assess the quality of the structure after the final round of 
refinement, which gives details about the bond length violation, bond angle
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violation, planarity of the molecule and also Ramachandran plot. WHATIF 
(Vriend 1990) is a program for structure analysis, MOLPROBITY (Davis et al. 
2004) is a program to validate the structure and contacts in the structure. The 
final step after structure validation is submission to the Research 
Collaboratory for Structural Bioinformatics Protein Data Bank (www.rcsb.org).
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Fig 1.9 A diagramatic representation of Ramachandran plot. The unit of O 
and are in degree. Regions shaded in grey are the allowed regions of 
Ramachandran plot for respective secondary structure, while the regions 
shaded with yellow are the generously allowed regions of Ramachandran plot.
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Recent Advances
Improvements in science and technology lead scientists to search for answers 
in many different ways. In the late 20th century several genomic projects 
deposited the complete genome of organisms including human genome into 
the public database. This opened the door to the researchers in different field 
of sciences and gave rise to new branch of sciences called 
Bioinformatics/Computational Biology, Structural Genomics/Proteomics, and 
Microarray technology (Appendix I). Also, X-ray crystallography has seen a 
significant development in the last decade that becomes very clear by looking 
at the growth rate of three-dimensional structures submitted in the Protein 
Data Bank.
Synchrotrons play a very important role and are an indispensable tool to 
structural biologists and to scientists in many other fields. The high intensity 
and high energy X-ray beam generated at Synchrotrons has reduced the X- 
ray diffraction data collection from days to hours and/or minutes. Time taken 
to solve protein crystal structures has decreased from months to days with the 
help of synchrotron radiation source, automation and robotics in this field. To 
date 3rd generation synchrotrons produce X-radiations of very high strength 
(3GeV - 7GeV) for scientific experiments. Synchrotrons not only generate X- 
radiations for structural biology, but also, ultraviolet radiations, LASER, X- 
radiations for medical scanning, etc.
Recent advancement and application of robotics in structural biology from 
crystallisation to data collection has made structural study a high-throughput 
one. Crystallisation robots can setup thousands of crystallisation trials in a day 
only using nanolitres of protein sample and can analyse the drops and report 
any success in them. In X-ray diffraction data collection robots are now used 
to mount the crystal, orient the crystal in the beam and to collect data. 
Automation in structure solution has been successfully tested on well known 
protein lysozyme by the application of robotics. Advances in Computational
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Chemistry and Combinatorial Chemistry have opened the door to the drug 
companies towards rational design of drugs.
Though there observed significant development in all the fields the ratio of 
available three-dimensional structures to the gene sequences when 
compared is very low. This is because various techniques used to determine 
three-dimensional structure has bottlenecks to overcome. Availability of pure 
protein, crystallisation, and quality of the crystal and diffraction data are major 
checkpoints in X-ray crystallography.
In parallel with advancement in X-ray crystallography, developments were 
also reported in Molecular Biology and Protein Biochemistry. Novel 
techniques and developments in available methods for protein expression and 
purification are a boost to modern biology. Successes using different 
expression systems like yeast, viruses, insects, and mammalian cell lines are 
of very recent development in expression of mammalian proteins and many 
others where the traditional bacterial system fails. Automation and 
developments in protein purification techniques (section 1.4.2) and 
parallelisation of successive purification steps have limited the amount of 






Clostridial neurotoxins (CNT) are the most potent toxins known and are 
produced by the anaerobic bacteria of the genus Clostridium (Schiavo et al.
1994). This rod shaped anaerobic bacteria is commonly found in soil (Fig 2.1). 
The bacterial spores of Clostridium botulinum undergo hibernation until 
exposed to conditions that support their growth. Clostridium botulinum, 
Clostridium butyricum, Clostridium barati and Clostridium tetani are the 
causative agents of botulism and tetanus (Burgen et al. 1949; Kao et al. 1976; 
van Ermengem 1979; Simpson 1981). Botulism is a neuroparalytic disease 
caused by the neurotoxins produced by the anaerobic bacteria Clostridium 
botulinum. The symptoms of botulism include double vision, blurred vision, 
drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle 
weakness. If untreated, these symptoms may progress to cause paralysis of 
the arms, legs, trunk and respiratory muscles. The botulinum neurotoxin 
(BoNT) blocks the release of neurotransmitter at the nerve terminal (Humeau 
2000; Lalli et al. 2003). There are three main kinds of botulism:
1. Food-borne caused by ingestions of the BoNT’s.
2. Wound botulism -  entry of the BoNT’s through an open wound.
3. Infant botulism -  caused by the bacillus spores in the infant 
intestine.




There exist seven different serotypes of BoNT’s (A-G) (Lowenthal and 
Lamanna 1953; Kitamura et al. 1968; Kozaki et al. 1974; Ohishi and 
Sakaguchi 1975; Sugii and Sakaguchi 1975; Miyazaki et al. 1977; Iwasaki and 
Sakaguchi 1978). These toxins are synthesized as a single polypeptide chain 
(-150 kDa) (Beers and Reich 1968; Dasgupta and Sugiyama 1972a; b; 
Miyazaki et al. 1977). This single chain is subsequently cleaved to produce 
two chains: a single Light chain/catalytic domain (LC) (~50 kDa) and a Heavy 
chain (HC) (~100 kDa). The heavy chain is further divided into two 
subdomains -  the N-terminal half (-50 kDa) called the translocation domain 
(Hn) and the C-terminal half (-50 kDa) called the ganglioside binding domain 
(He) (Fig 2.2a-b). A single disulphide bridge between residues Cys441- 
Cys450 links the HC and LC domains. The position of the cysteines in the 
amino acid sequence differs in different serotypes.
The He domain is further sub-divided into two subdomains (Fig 2.2a-b), which 
are composed of mainly p-sheet topology, joined by a a-helix. The jellyroll 
topology of the N-terminal sub domain of He domain is similar to the one 
found in lectins (Turton et al. 2002) and is well conserved among the CNT 
family. The Hn domain consists of a pair of long (105A) amphipathic helices, 
which resembles the ‘coil-coif motif as observed in some viral proteins (Turton 
et al. 2002). It is believed that the Hn domain might be involved in the 
translocation of LC domain into the cytosol by forming pores through the cell 
membrane. This domain contains a long flexible belt, which wraps the LC 
domain and occludes the active site of BoNTs, thus preventing access to the 
bound important zinc ion.
Several botulinum neurotoxin structures have been reported in the protein 
data bank. These structures includes light chain of serotypes A (PDB: 2G7K), 
B (PDB: 1F82), D (PDB: 2FPQ), E (PDB: 1T3A), F (PDB: 2A8A), and G (PDB: 
1ZB7), binding domain of serotype B (PDB: 1ZOH), and whole toxin structure 
for serotypes A (PDB: 3BTA) and B (PDB: 1EPW) only.
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446 Hn 384 885 Hc 1310
Translocation domain Binding domain
Fig 2.2a Schematic representation of domain organisation in Clostridium 
botulinum toxins.
Fig 2.2b Ribbon representation of botulinum neurotoxin B (Thiyagarajan et 
al., unpublished results). Catalytic domain (light chain) -  cyan; translocation 
domain HN -  brown; Binding domain -  Hc: HCn -  green; HCc -  violet; Catalytic 
Zinc ion -  blue; Calcium ion -  green; sulphate ion and glycerol molecules are 
shown as ball-and-stick models.
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2.2 Sequence Similarity of BoNTs and TeNT
CNT family consists of botulinum neurotoxin (BoNT) and tetanus neurotoxin 
(TeNT). CNTs share an overall sequence similarity of 30 % - 40 % within the 
family (Binz et al. 1990). Light chains of CNTs share a high sequence 
similarity within themselves and thermolysin, a zinc dependent 
metalloprotease (Holden et al. 1987). All CNTs possess three functional 
domains each involved in definite function (Fig 2.2b). CNTs could have 
evolved from a single ancestral gene (Ahnert-Hilger and Bigalke 1995) with 
high sequence similarity and conserved domain architecture (Lacy and 
Stevens 1999).
The LC domain contains a conserved zinc-binding HExxH motif, characteristic 
of zinc proteases (Montecucco and Schiavo 1993)(Fig 2.2c). The genbank 
accession numbers for the sequences in Fig 2.2c are A: 20137335; B: 
399134; C: 1217587; D: 115188; E: 399136; F: 399137; G: 2499920. The light 
chain is a zinc-dependent endopeptidase, specific for the SNARE 
components (section 2.3) involved in neurotransmitter release (Schiavo 2000; 
Turton et al. 2002). Catalysis of proteolytic cleavage of SNAREs is mediated 
by BoNTs LC domain leaving SNARE complexes non-functional, thus, 
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Fig 2.2c Conserved zinc binding motif HExxH observed in all seven 
serotypes.
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Fig 2.2d Catalytic centre of the endopeptidase. Zinc ion -  gold; water -  cyan; 
coordinating residues are shown as ball-and-stick model (Thiyagarajan et al., 
unpublished results).
2.3 Control of Neurotransmission by SNARE Complexes
Neurotransmission is controlled and regulated by a special group of proteins 
called SNARE (soluble N-sensitive factor attachment protein receptor), which 
includes VAMP (vesicle associated membrane protein), the plasma 
membrane protein syntaxin, and the SNAP-25 (synaptosomal-associated 
protein) (Bajjalieh 2001). The SNARE complex formation involves one 
VAMP/syntaxin or two SNAP-25 molecules, which is the requirement for 
vesicle fusion at the nerve terminals (Chen 2001). A mechanism for SNARE 







Fig 2.4 The SNARE complex formation (Chen 2001). Before priming all 
SNARE proteins are free in the cytosol, syntaxin is thought to be attached to
Zippering
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munc 18 (Haynes et al. 1999; Rickman and Davletov 2005). ATP-dependent 
priming binds the VAMP to SNAP-25 and Ca2+ dependent triggering mediates 
the binding of syntaxin to the VAMP - SNAP-25 complex. This loose complex 
‘zippers’ into a tight, SDS-resistant four-helix bundle, which helps in fusion of 
the SNARE to the plasma membrane.
The reduction of disulphide bond between light chain and heavy chains of 
CNT is critical for toxins activity in the host, which is supposed to take place in 
the endosome. Following the separation of light chain and heavy chain the 
catalytic part of the enzyme is released into the cytosol. It is not yet 
completely understood, the mechanism about the translocation of the light 
chain into the cytosol. The hypothesis is that the translocation domain and the 
catalytic domain undergo a major structural and conformational change at 
endosomal pH (5.0) (Schmid et al. 1993; Kalandakanond and Coffield 2001), 
allowing the translocation domain to form pores on the cell membrane. The 
catalytic domain also undergoes a little conformational change at endosomal 
pH retaining its zinc site. This conformational change of catalytic domain is 
completely reversible at cytosolic pH (Puhar et al. 2004). Similar type of 
toxification is observed in case of diptheria toxin (Kagan et al. 1981).
2.4 Substrate Specificity and Toxicity
All CNTs are zinc proteases and are toxic to neuronal cells by inhibiting the 
release of neurotransmitter across the nerve terminals. Toxification by BoNTs 
or TeNTs involves the toxin binding to ganglioside receptors on the cell 
surface followed by intoxication -  receptor mediated endocytosis (Black and 
Dolly 1986a; b; Montecucco 1986). The target for TeNTs and BoNTs are 
different. TeNTs affect the central synapses while the BoNTs affect the 
cholinergic nerve terminals. Studies have shown that the potential toxic 
fragment in the process of inhibition of exocytosis is the light chain of BoNTs 
and TeNTs (Ahnert-Hilger et al. 1989). The special features of CNTs are that
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the toxins are synthesised as an inactive precursors, which becomes active 
on subsequent proteolytic cleavage in the host (Montecucco and Schiavo 
1993). The presence of zinc ion is very important for these endopeptidases. 
Removal of zinc completely abolishes the substrate specificity and activity of 
CNTs in the host (Tonello et al. 1997). Substitution of other divalent metal 
ions retains some activity of the enzyme (Tonello et al. 1997; Eswaramoorthy 
et al. 2004).
Despite high sequence similarity between BoNT serotypes their substrate 
specificity is very selective (Schiavo et al. 1993; Binz et al. 1994; 
Vaidyanathan et al. 1999) (Table 2.1). Whilst the substrate specificity, BoNTs 
show a requirement for length of the substrate it binds (Shone et al. 1993; 
Pellizzari 1996). This indicates that the substrate specificity of BoNTs is not 
decided by the active site, but a few exosites located around the active site 
(Breidenbach and Brunger 2004). In turn the SNARE proteins share a 
common nine-residue motif, thought to undergo structural conformational 
change upon binding to the BoNTs (Rosseto et al. 1994; Wictome et al. 1996; 
Breidenbach and Brunger 2004).
Table 2.1 Substrate specificity and scissile bond selectivity of light chain of 
BoNTs. SNAP-25: synaptosomal associated protein, a 25 kDa protein; VAMP- 
2: vesicle associated membrane protein, also called as synaptobrevin II.
BoNTs SNARE Substrate Scissile bond
A SNAP-25 Q 197-R198
B Synaptobrevin II Q76 -  F77
C Syntaxin, SNAP-25 K253-A254, R198-A199
D Synaptobrevin II K59 -  L60
E SNAP-25 R180 —1181
F Synaptobrevin II Q58 -  K59
G Synaptobrevin II A81 -A 8 2
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2.5 Mechanism of action
Proposed mechanism of activation of the catalytic domain (LC) of botulinum 
neurotoxin (Fig 2.5):
1. Binding of the BoNT to the gangliosides (Simpson and Rapport 
1971b; a) of the neuronal cell membrane. The residues involved in 
putative ganglioside binding include Ser1287, Trp1289, Tyr1290 
and Gly1300 and is conserved in both TeNT and BoNT. The 
residue Asp1222 in TeNT is replaced with glutamic acid in BoNTs 
(Ginalski et al. 2000).
2. The bound toxin is endocytosed into the presynaptic vesicle 
(Montecucco 1986; Ginalski et al. 2000; Humeau 2000)
3. Following the endocytosis it is proposed that there is a pH- 
dependent structural change of the toxin occurs, which release 
catalytic domain (LC) into the cytosol (Montecucco 1994; 
Maksymowych and Simpson 1998; Puhar et al. 2004).
4. Inhibition of neurotransmitter release is initiated by binding and 
proteolytic cleavage of SNAREs.
2.6 Therapeutic use of Botulinum Neurotoxins
Botulinum neurotoxins are the causative agents of botulism, a neuroparalytic 
illness for which there is no drug/vaccine widely available to date. This could 
be a reason why this toxin is so extensively studied. But, this is not true, as 
the botulinum neurotoxins has much more interesting properties and used in 
many clinical applications. The longevity effect of the toxin makes it a suitable 
target in therapeutics. BoNT/A is very well known by the trade name BOTOX® 














Turton ef al 2002
Fig 2.5 Proposed mechanism of BoNTs entry and release of the catalytic 
domain into the cytosol (Montecucco 1994; Turton et al. 2002).
Other clinical applications are treatment of cervical dystonia (Greene et al. 
1990), achalasia (Annese et al. 1998), blepharospasm (Jankovic and Orman 
1987), spasticity (Snow et al. 1990; Simpson et al. 1996), autonomic disorders 
such as anal fissure (Maria et al. 1998; Naumann et al. 1999). It is studied 
that BoNT/A can inhibit overactive nonmotor and motor peripheral 
acetylcholine neurons (Silberstein et al. 2000) resulting in reduced 
hyperactivity of muscles and spasm. The side effects and proper analysis of 
drug administration indicated that BoNT/A could be used in pain relief 
(Silberstein et al. 2000) such as chronic pain (Rollnik et al. 2001), cervical 
dystonia, and migraine (Silberstein et al. 2000). Intravenously injected 
clostridial spores become exclusively localised to the hypoxic/necrotic tissue 
common to solid tumours and thus the clostridial spores could be 
administered as a drug delivery vehicle in the treatment of cancer 
chemotherapy (Minton et al. 1995).
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Inhibitors of Botulinum Neurotoxins
Botulism can be spread air-borne by the spores of botulinum and hence, there 
is a threat that Clostridium botulinum could be used as a bio-weapon 
(Leggiadro 2000). Symptoms appear from 12 hours to 6 weeks from toxin 
infection and diagnosis of botulism is not a routine practice in clinical 
laboratories. Since there is no effective cure available yet, side-effects from 
clinical use of the toxin and threat as a bio-weapon makes it a hot molecule in 
research. Several agents to detoxify the toxicity of the toxin have been 
identified (Mikhailov and Mikhailov 1970), but, this could only be used to delay 
the onset of paralysis and not a preventive one (Simpson 1986; Deshpande et 
al. 1997). Several serotype specific small molecule inhibitors and peptide 
inhibitors of botulinum neurotoxins have been reported (Satoh et al. 2001; 
Anne et al. 2003a; Anne et al. 2003b; Burnett et al. 2003) but in early stages 
of identifying the lead compound(s) and not recommended for use in 
therapeutics. Further studies on toxins structural and chemical property i.e., 
the mechanism of toxins binding to the pre-synaptic membrane, release into 
the cytosol from the endocytosed synaptic vesicle and substrate specificity 
would need to be elucidated in order to use botulinum toxin as an effective 
therapeutic.
2.7 Novel non-toxic LHn fragments
Inactivation of the botulinum neurotoxin by proteolytic action of trypsin on the 
C-terminal residues of the binding domain and the formation of channels in 
bilayers by the translocation domain has been reported (Shone et al. 1985; 
Donovan and Middlebrook 1986; Blaustein et al. 1987; Shone et al. 1987). 
Hence the deadliest toxin becomes non-toxic or inactivated upon 
removing/losing the binding domain. This information is applied in the creation 
of novel non-toxic light and heavy chain (LHn) fragments of botulinum 
neurotoxin -100 kDa in molecular weight, which comprises only the light chain 
(LC) and the translocation domain (Hn) of the heavy chain (HC). The non-
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toxic LHn fragments are engineered to resemble the native toxin lacking the 
cell surface-binding domain. Application of recombinant technology in the 
creation of novel non-toxic fragments of botulinum neurotoxin have been 
reported (Chaddock et al. 2002; Duggan et al. 2002; Chaddock et al. 2004; 
Turton et al. 2004; Sutton et al. 2005; Foster et al. 2006). Suitable ligands are 
selected, designed and/or researched for use in retargeting the non-toxic LHn 
fragments as a therapeutic. Studies on retargeting the LHn fragments in mice 
and their effects have been reported (Chaddock et al. 2000a; Chaddock et al. 
2000b; Chaddock et al. 2004; Sutton et al. 2005; Foster et al. 2006).
Though whole and part (catalytic domain only) of botulinum toxins structural 
information is available the innate properties - mechanism of toxin’s 
neurotoxicity, substrate specificity and substrate length selectivity are not yet 
structurally characterised. In contrast there is no structure available for non­
toxic LHn fragments. The LHn fragments retain the intrinsic neurotoxic 
property even in the absence of cell-binding domain/ligand, i.e., the toxin 
remains inactive unless endocytosed after binding to cell-surface with its 
binding domain/ligand (absent in LHn fragments) and activated by reduction 
of disulphide bond bridging between light chain and heavy chain fragments. 
Understanding the structure of LHn fragments and using it for structure-based 
drug design would help in harnessing the use of LHn molecules as a 
therapeutic and drug for cure in botulinum infection. Initial homology modelling 
suggested that the LHn fragments should also possess similar structure to the 
native toxin, the only difference being is the absence of the binding domain 
(Fig 2.6). Yet this is only a model and a proper structural and chemical 
characterisation is a prerequisite to understand these novel molecules to be 






Fig 2.6 Ribbon diagram representation of homology model of LHn/A (Details 
of homology modelling in section 2.8)
2.7.1 Initial crystallisation screens for LHn/A and LHn/C
Initial crystallisation screens of LHn fragments were performed with the 
recombinant proteins provided by Dr. John Chaddock. The LHn proteins were 
in buffer 50mM Hepes pH 7.2 and traces of phosphate salts. The proteins 
were provided in the lyophilised form. Initial protein concentration of -10 
mg/ml was used for standard screens (Structure screen I and II (Molecular 
Dimensions, Ltd, UK), PEG/lon screen, and Ammonium sulphate grid screen 
(Hampton Research, USA)). The crystallisation setups were carried using the 
hanging drop vapour diffusion technique using 24-well linbrow plates 
(Molecular Dimensions Ltd., UK). The drops containing equiproportion of 
protein to mother liquor is equilibrated against 500-1000 pi of the reservoir 
solution and incubated at 16° C. Immediate precipitation was observed in
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most of the structure screen conditions. Drops were observed for any hit after 
24 hours of setup. Repeated checks for months, and self-designed screens 
(Combinations of PEG, Ammonium Sulphate, MPD, different buffers at 
different pH, additives, use of detergents) and some of the conditions 
previously reported for the whole or part (light chain) of the toxin were also 
screened. Whilst waiting for a hit from the crystallisation setups, report of 
successful crystallisation and improvement in resolution of the diffraction data 
by surface engineering of protein molecules by Derewenda et al. directed to 
try a different approach of mutating the surface residues or residues that 
might hinder the crystal contacts of LHn fragments (Derewanda et al., 2004).
2.7.2 Site-directed Mutagenesis to Aid Crystallisation of LHn Fragments 
Type A
All the work relating cloning, mutation, expression and purification were 
carried out at Health Protection Agency (part of this organisation is now called 
Syntaxin Ltd.), Porton Down, Salisbury. The clones for LHA-S877, LHC-EGF, 
and LHC-HT were provided Dr. John Chaddock to start the experiment except 
where mutation or reengineering or recloning the gene into a different vector 
is carried out. Modified pMAL vectors were used for all cloning work and 
expression systems (section 2.8).
The LHn/A is purified in the native and mutant forms. LHn/C is purified either 
with C-terminal His-tag and/or as a fusion protein with Epidermal Growth 
Factor (EGF) and hereafter referred as LHC-HT and LHC-EGF respectively. 
All the genes were cloned and expressed in Escherichia coli BL21 cells either 
with cleavable N- or un-cleavable C- terminal His-tag and with cleavable N- 
terminal MBP-tag or without N-terminal MBP-tag following induction with IPTG 
(isopropyl-beta-D-thiogalactopyranoside). A detailed protocol from expression 
to purification and assays is given in section 2.8 along with the gel pictures.
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The LHn/A protein initially used for crystallisation trials were 871 amino acids 
in length which was later increased to include the full translocation domain 
(877 amino acids in length). The increase in length was to stabilise the 
translocation domain and thought the extended version of LHn/A would favour 
crystallisation unlike the short version (871 amino acids). Molecular modelling 
of LHn/A and comparative analysis with other available whole toxin structure 
gave a direction to proceed. The whole length of LHn/A-S877 (an extended 
version of 871 amino acids) including the complete translocation domain 
sequence (877 amino acids in length) was submitted to the Swiss-protein 
modelling server, an automated protein homology modelling server.
2.7.3 Homology modelling of LHn/A
Molecular modelling of LHn/A is done using the Swiss-MODEL 
(http://swissmodel.expasv.Org//SWISS-MODEL.html). an automated 
comparative protein modelling server. From the sequence comparison results 
the structural data of botulinum neurotoxin A (PDB: 3BTA) (Lacy et al., 1998) 
was selected as the target template for homology modelling and for further 
comparative studies. The LHn/A model were completely biased by its 
template. Hence, a round of energy minimisation was carried using the 
software suite Crystallographic and NMR System (CNS) (Brunger 1998). The 
side of the translocation domain interacting with binding domain in the whole 
toxin is solvent exposed in the non-toxic LHn fragments. Hence the 
suspection is on the crystal contacts of the solvent exposed part of the 
translocation domain of LHn fragments. Hence to aid crystallogenesis site- 
directed mutagenesis experimental studies were done.
All the mutation works were carried out in the LHn/A-S877 (hereafter referred 
as LHA-S877) background. Three strategies were tried to improve the stability 
of the protein regions in the translocation domain leaving the catalytic domain 
undisturbed. LHA-S877 is also expressed, purified and screened for 
crystallisation trials.
55
- Stabilisation of loop 1 by mutating K625A and I626A. (Fig 2.7a). 
The residues K625 and I626 in the loop were thought to be involved 
in crystal contact of LHn/A. Based on interactions observed for 
these residues with the binding domain in whole toxin, predictions 
were made that the residues K625 and I626 could disturb the 
crystal formation.
- Stabilisation of helices 2 and 4 (Fig 2.7b) by introducing a 
disulphide bridge between the residues V793 and T865. These two 
mutations were considered to lock the helix 4 to helix 2 by forming a 
disulphide bridge.
- Mutation at the tip of helix 3 to favour the interaction with the 
neighbouring polar residues of helix 2 (Fig 2.7c).
Fig 2.7a Homology model of LHA-S877 - Residues in loop K625 and I626 are 






Fig 2.7b Homology model of LHA-S877 - Residues between helices 2 and 4, 
V793 and T865 are mutated to cysteines. Disulphide bridge is shown as 
yellow stick, the cysteine residues in grey ball-and-stick model.
h e lix  4
h e lix  2
h e lix  3
Fig 2.7c Homology model of LHA-S877 - Residue in the loop region between 
helix 2 and 3, L845 is mutated to either lysine or asparagine.
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2.7.4 Preliminary Diffraction Data for LHA-S877, LHC-HT and LHC-EGF 
Fusion Protein
2.7.4.1 Materials and Methods
LHn fragments of type A and its mutants, and type C with N-terminal MBP-tag 
and a C-terminal His-tag and as a fusion protein with EGF were expressed in 
E.coli BL21 cells in Terrific Broth, which is inoculated from a overnight culture. 
The cultures were grown until an optimal optical density at 600 nm is reached 
prior to induction with IPTG and further grown for ~20 hours (section 2.8). The 
cells were harvested by centrifuging the cultures at ~4000 rpm (revolutions 
per minute) for ~20 min and the pellets were resuspended in the lysis buffer 
and stored at -80°C. Cells were lysed by sonication and spun at 18000 rpm in 
a Beckman JLA rotor for ~25 min. The protein was expressed in soluble form, 
hence the pellet is discarded and clear lysate was loaded on to the Ni2+- 
chelating sepharose column. The bound proteins were eluted with different 
concentration of imidazole and ran on an SDS-PAGE gel to identify the 
fractions containing the protein of interest. To ensure that the maximum purity 
is achieved the eluted sample was again ran on second Ni2+-chelating 
sepharose column, this time the His-tag or MBP tag in the N-terminal of the 
LHn fragments are cleaved by Factor Xa treatment (section 2.8). Final tuning 
in purification step was achieved by running the purified sample through size- 
exclusion chromatography column (section 2.8). The sample fractions were 
run on SDS-PAGE gels and checked for purity (Fig 2.15). The fractions were 
pooled and concentrated for crystallisation trials. The concentration of the 
protein samples was either measured using ultraviolet absorbance spectrum 
or BCA assay. The concentrated sample was finally ran on SDS-PAGE to 
check the final purity of the sample and stored at -20°C but not lyophilised.
Crystallisation of LHn fragments were carried out using the standard 
crystallisation matrix bought from Molecular Dimensions Ltd., UK, and 
Hampton Research, UK. Self-designed screens were also screened. All the
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crystallisation setups were performed using the hanging drop vapour diffusion 
method as described in section 2.7.1.
2.7.4.2 Crystals of LHA-S877, LHC-EGF and LHC-HT
LHA-S877
Crystals of LHA-S877 were observed in two of the structure screen conditions 
after a period of ~10 months. Protein concentration used was 10 mg/ml. The 
conditions were
1. 30 % PEG 4000; 0.2 M Ammonium Sulphate; 0.1 M Tris-HCI pH 8.0
2. 0.8 M Ammonium Sulphate; 0.1 M Sodium citrate pH 5.0
Crystals obtained from condition II was not eproducible but the crystals 
diffracted to 6.0 A resolution (Fig 2.8a). The diffraction pattern was measured 
at SRS, Daresbury at PX station 14.1 (A = 1.488 A) with crystal oscillation 
range of 1°, 120 sec exposure to X-radiation at cryo temperature of 100K. The 
crystal was cryo-protected with 25 % glycerol prior to mounting on the 
goniometer. There is no crystal picture taken for this condition. In contrast to 
condition 2, condition 1 was eproducible and used for further optimisation 
trials. Hundreds of tiny crystals (Fig 2.8b) grow in a period of 7-10 days using 
condition I. These crystals were not suitable for diffraction studies. Hence, 
optimisation of the condition was carried out using additives such as glucose, 
MPD (2-methyl-2,4-pentanediol), glycerol, metal ions like nickel, copper, iron 
were also used. Nothing appeared in most of the additive screens for weeks. 
Detergents were also used as additives bearing in mind that the LHn 
fragments have a transmembrane region, the Hn domain that might help in 
growing better crystals. One of the conditions using Hecameg detergent gave 
long needle crystals (Fig 2.8c). Optimisation of this condition is currently 
underway.
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Fig 2.8a First X-ray diffraction pattern of LHA-S877. Diffraction image 
recorded at PX station 14.1 (A = 1.488 A), SRS, Daresbury with oscillation 
range of 1°, exposure = 120 sec.
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Fig 2.8b Microcrystals of LHA-S877. 30 % PEG 4000; 0.2 M Ammonium 
Sulphate; 0.1 M Tris-HCI pH 8.0
Fig 2.8c Needle crystals of LHA-S877 using hecameg detergent as additive.
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LHC-EGF
Crystals of LHC-EGF were observed in one of the structure screen conditions. 
The crystals appeared after a month from setup date. Protein concentration 
used was ~8 mg/ml. The condition is
10 % PEG 1000 and 10 % PEG 8000
Thin plate like crystals (Fig 2.9a) grew in repeating the experiment with same 
condition. Optimisation with varying concentrations of the precipitant or 
addition of additives and detergent screen did not give any better result. The 
crystal did diffract to -4.0 A resolution. The diffraction pattern was measured 
at SRS, Daresbury at PX station 14.2 (A = 0.979 A) with crystal oscillation 
range of 1°, 120 sec exposure to X-radiation at cryo temperature of 100K. The 
crystal was cryo-protected with 25 % glycerol prior to mounting on the 
goniometer. The crystal lost its diffracting strength after a couple of snapshots 
(Fig 2.9b).
Fig 2.9a Thin plate crystals of LHC-EGF
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Fig 2.9b First X-ray diffraction pattern of LHC-EGF. Diffraction image 
recorded at PX station 14.2 (A = 0.979 A), SRS, Daresbury with oscillation 
range of 1°, exposure = 120 sec.
LHC-HT
Crystalloids of LHC with C-terminal His-tag (Fig 2.9c,d) were observed in two 
of the structure screen conditions. Protein concentration used was -2  mg/ml. 
The crystals appeared in less than a week from setup date. The conditions 
are
1. 0.1 M Sodium citrate pH 5.6; 1.0 M Ammonium dihydrogen phosphate
2. 4.0 M Sodium formate
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Fig 2.9c Condition 1: 0.1 M Sodium citrate pH 5.6; 1.0 M Ammonium 
dihydrogen phosphate
Fig 2.9d Condition 2: 4.0 M Sodium formate
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2.8 Cloning, Expression, and Protein Purification of recombinant LHn 
Fragments
Following the homology modelling and analysis of the recLHn/A fragment 
model, following interpretations were made: the loop region interacting 
(section 2.7) with the binding domain He (absent in recLHn) might interfere 
with crystal packing (due to high thermal vibrations) and thus not allowing the 
protein to form crystals. These observations lead us to try some mutational 
studies on this region. Six residues were K625, 1626, D628, K646/Y647, D650 
and 1656, which might interfere with the crystal packing, and also to extend 
the Hn domain by a few residues (to restrict the movement of the loop). The 
desired mutations were K625A, K625A+I626A, I626A, triple mutants (V793C, 
T865C, L845K/N), and LHn/A truncation at residue 1830.
The mutations were introduced in the S877 extension (S877 - six residues 
were added to the C-terminal (terminating with residue S) of the Hn domain 
which was previously 871 in length). Since all the mutation and/or truncation 
work were only in HN domain of LHn/A the pTO vector with Hn domain only 
used for PCR reactions unless otherwise mentioned. The LHn/A is cloned in 
an modified pMAL vector (Fig 2.10) with restriction sites Pst I and Xba I for Hn 
domain and the whole length of the LHn domains of serotype A and/or C were 
between restriction sites BamH I and Hind III. All the mutations were carried 
out in the Hn extension (S877) template (synthesized with Pst I and Xba I 
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Fig 2.10 A simple diagramatic representation of the plasmid constructs
66
2.8.1 Materials and Methods
Mutant recLHn expression and purification was done at HPA, UK. The BL21 
chemically competent cells bought from Novagen (catalogue number 69499- 
4), TOP10 chemically competent cells bought from Invitrogen (catalogue 
number C4040-06). pTO vector is the pCR 4-TOPO vector from Invitrogen. 
pHx vector was the one prepared in Dr. John Chaddock’s laboratory, Health 
Protection Agency (part of this organisation is now called Syntaxin Ltd.), 
Porton Down, Salisbury. The His-tag was inserted into the pMAL-c2x vector 
from New England Biolabs (NEB) in place of the MBP tag. A small section of 
the pMAL plasmid has been removed to make it non-transmissible. The 
mutant primers were PCR amplified, sequence verified, cloned into 
expression vectors and expressed. All the primers for mutation work were 
synthetically prepared and bought from MWG and/or Sigma-genosys, UK. All 
the reagents for PCR reaction were bought from Stratagene, UK. The DNA 
purification reagents were bought from Qiagen, UK, Promega, UK and 
Stratagene, UK. Chemical compounds and salts used for protein expression 
and purification were bought from Sigma, UK. Readymade SDS-PAGE gels 
were bought from Invitrogen, UK.
Expression of recLHn fragments:
NOTE: All recLHn plasmids used were ampicillin resistant. Following 















pHx- = cleavable N-terminal His-tag
pHMx = cleavable N-terminal His-MBP-tag
pMxH = cleavable N-terminal MBP-tag and non-cleavable C
terminal His-tag




PCR amplification of the mutants:
Each PCR reaction (for single mutation or truncation work) were carried out in 
a PCR machine using the standard protocol recommended by Stratagene 
and/or Qiagen. The Tm values for primers were calculated theoretically using 
the formula
Tm = 81.5 + 0.41 (%GC) -  675/N - %mismatch 
where, Tm - melting temperature
%GC - percentage of GC content of primer
Designed primers for constructs 2, 3, 4, 6, 7/8, 10 and 11 were commercially 
synthesised and bought from MWG and/or Sigma-genosys. PCR products 
were sequence verified from Lark Technologies Inc.
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A general PCR protocol used is given below:
Materials required: 10x PFu buffer, plasmid DNA template, primer mixes, 
dNTPs, DNA polymerase.
For a 50 pi reaction: add 5 pi of PFu buffer, 1 pi of template, 2.5 pi of primer 
mix at ratio 1:1, 1 pi of dNTP, 39.5 pi of double distilled water and 1 pi of 
Turbo DNA polymerase.
A three-step PCR cycle is given below:
1. Initial activation step at 95° C for 1 min
2. Repeat l-l 11 for 16 cycles
I. Denaturation step at 95° C for 1 min
II. Annealing step at 55° C for 1 min
III. Extension step at 68° C for 12 min
3. Final hold at 4° C
1 pi of Dpn I enzyme at a concentration of 10 units/pl was added to the final 
PCR product and incubated at 37° C for approximately 3 - 5  hours. The Dpn I 
treated PCR products were ligated into pTO vector and then transformed into 
TOP 10 competent cells. The transformed products were applied on an 
ampicillin resistant agar medium and incubated at 37° C overnight for colonial 
growth of the plasmid.
All PCR reactions were not straightforward. In case of construct number 6 for 
pHMx-LHA-1830 truncation variable concentration of MgCh was used in a 
temperature gradient PCR with different annealing temperature from 45° C -  
65° C (Table 2.4) and a different DNA polymerase (HotStarTaq) from Qiagen 
were also tried.
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Table 2.2 Gradient PCR setup for pTO-Hn-1830
DNA polymerase MgCI2 (mM) Annealing temperature 
(°C)
HotStarTaq (Qiagen) 0.0/1.572.5/4.5 45/55/65
PFu Turbo (Strategene) 2.5 45/55/65
The PCR reactions setup with PFu turbo in the presence of MgCk and at 
different annealing temperatures was successful and sequence verified.
In case of triple mutants there was a serious problem with one of the mutant 
primers designed (V793C). Despite different temperature gradient 
concentration and MgCh concentration, the mutation failed to give a 
successful result. Hence the primers were redesigned; one shorter and one 
larger than the primer used and the PCR reactions were setup. The short 
length primer (25 bases in length) gave a successful result by following the 
standard Stratagene protocol. Addition of MgCfe did not help the PCR 
reaction, instead gave negative results. But, temperature gradient from 45° C 
-  68° C did not exhibit any difference in the reaction cycles.
Ligation of the sequence verified constructs:
All the mutation and/or truncation work were carried out in pTO vector with 
restriction sites Xba I and Pst I. The pTO vector and pHx/pHMx/pMxH 
modified pMAL vectors were double digested with Xba I and Pst I at 37° C on 
a water bath for approximately 1 - 2  hours. The digested samples were then 
run on a 0.8 -  1 % agarose gel electrophoresis at 110 V - 120 V for 
approximately 50 minutes. The required fragments were gel purified using 
Promega DNA purification kit using the protocol recommended. The pTO-Hn 
domain with the required mutation and/or truncation is double-digested, gel 
purified and ligated into the modified pMAL expression vectors (Fig 2.17) 
using Stratagene ligation kit.
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Transfer of LHA-S877 from pHx- vector to pHMx- vector were tried to see any 
better expression of the protein in a different plasmid with MBP at N-terminus. 
The pHx-LHA-S877 and pHMx- vectors were sequentially digested with BamH 
I and Hind III restriction enzymes and any one of the digested sample was 
treated with calf intestinal mucosa (CIP) to avoid recircularisation of the 
plasmid by removing the 5’-P04‘ from the DNA. Care was taken not to treat 
both the insert and plasmid with CIP before the ligation reaction was setup.
An overview of expression of the constructs:
- Overnight culture (50 - 100 ml) of the respective recLHn strain was 
grown in either Modified TB (Terrific Broth) / LB (Luria Broth) medium in 
the presence of 1 ml of 100 mg/ml ampicillin (final concentration of 0.1 
mg/ml) at 37° C in a conical flask shaking at 250 rpm.
- To 1 I of Modified TB 1 ml of 100 mg/ml Ampicillin and 10 ml of 20% 
glucose were added and the contents were emptied into a 2 I conical 
flask.
- The TB medium in 2 I conical flask was inoculated with 10 ml -  25 ml of
overnight culture and left in the shaking incubator (250 rpm) at 37° C.
- The absorbance/optical density at 600 nm (ODeoonm) were measured 
every hour.
- The temperature was lowered to 16° C once the optimal OD is reached 
(~0.5 -  0.6) and left for an hour to equilibrate.
- The cultures were induced with 1 ml of 1 M IPTG (final concentration of 
1 mM) and grown for approximately 20 hours at 16° C.
- After ~20 hr the cultures were harvested, the cell paste was weighed, 
resuspended in a small volume of buffer (0.1 M Tris-HCI pH 8.0, 0.15 M 
NaCI) and storedat -80° C.
- The average amount of cell paste yield per litre of culture was ~10 mg.
In case of LHA-S877 it was in the range of ~8- 10 g and LHC-
EGF/LHC-HT it was -10 -  15 g.
- 25 pi of the culture were taken to run on an SDS-PAGE system to 
check the expression.
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Fig 2.11 A sample expression SDS-PAGE picture for the triple mutant LHA- 
CKC-S877 and LFIC-FIT. Lane 1 is the BenchMark™ Protein Ladder 
(Invitrogen). Lanes 2-4 are the expression samples of pFIMx-LHA-S877; lanes
5-6 are for pHMx-LHC-HT
Protein Purification of recLHn fragments :
Sonication:
The cells were disrupted using sonication method at ~20-22 micron amplitude.
The cell paste was topped up with the buffer prior to sonication (say ~10-13 g
of cell paste was topped up to a volume of 40 -  50 ml i.e. 1 g of cell paste in 5
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ml of lysis buffer). A total of 10-12 cycles with 30 s on and 30 s off were 
carried. The cell paste was always kept on ice while sonicating, so as to keep 
the sample cool and to protect from the heat generated by sonication.
The sonicated sample was spun at 18,000 rpm at 4° C for 20 min. The clear 
lysate was decanted into a duran or falcon tube. The protein was expressed 
as soluble fraction. The equipments used for affinity chromatography were 
AKTA prime™/AKTA FPLC™, GE Healthcare. The columns used were XK 16 
and/or XK 26, Amersham Pharmacia Biotech (now called GE Healthcare). For 
SDS-PAGE; NuPAGE® Novex 4-12 % Bis-Tris Gels, NuPAGE® LDS Sample 
Buffer, NuPAGE® MOPS SDS Running Buffer from Invitrogen were used to 
run the protein samples. The gels were stained using SimplyBlue™ SafeStain 
Microwave protocol. The SDS-PAGE scanning instrumetn used was 
densitometer from Molecular Dimensions, UK. The concentrators used to 
concentrate protein were bought from Vivascience (polyethersulfone (PES) 
membrane). For BCA assay measurements Fluostar Optima from BMG 
labtechnologies was used.
Protein purification protocol short in detail:
Choice of Tris-HCI pH 8.0 buffer for protein purification:
Initially 50 mM Hepes pH 7.4 with 0.15 M NaCI was used as buffer in LHn 
fragment purification. But, later 0.1 M Tris-HCI pH 8.0, 0.15 M NaCI was used 
because of the following reasons:
1. Protein precipitates on concentration more than 2 mg/ml in 50 mM 
Hepes pH 7.4, 0.15 M NaCI. Hence, the samples are lyophilised (~0.2 
-  1.2 mg) in the presence of sodium phosphate buffer pH 7.4, 0.075M 
NaCI and 3 % Trehalose.
2. The lyophilised samples were resuspended in water or in the sample 
buffer for crystallisation trials (No precipitation observed after 
resuspension).
3. Crystallisation trials gave either precipitate or salt crystals.
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4. So, decided to go for an alternate buffer with/without salt in order to 
improve the method of purification.
5. Using Tris-HCI pH 8.0, 0.15 M NaCI as buffer, the final concentration of 
the protein was achieved to 1 0 -3 0  mg/ml, but the concentration was 
made to be 10 mg/ml.
6. Using 50 mM Hepes pH 7.4, 0.15 M NaCI as buffer the protein was 
eluted at 100 mM imidazole concentration where other impurities were 
also eluted. But, using 100 mM Tris-HCI pH 8.0, 0.15 M NaCI as buffer 
the protein was eluted at lower concentration of imidazole (30 -  40 
mM) containing less impurities when compared to the elution at 100 
mM imidazole. In Fig 2.19, Lanes 13-18 were eluted at 30 -  40 mM 
imidazole. Lane 20 was eluted at 100 mM imidazole.
7. Variable concentration (10 -  250 mM imidazole) of elution buffer was 
prepared using different volumes of imidazole stock solution in different 
volumes of buffer (0.1 M Tris-HCI pH 8.0, 0.15 M NaCI).
8. This choice of buffer helped to keep the protein sample in solution. 
Success has been achieved in crystallisation using Tris-HCI pH 8.0, 
0.15 M NaCI as buffer.
Affinity Chromatography 1:
i. Ni-affinity chromatography was used.
ii. The proteins have either N-terminal cleavable His-Tag (pHMx) or 
non-cleavable C-terminal His-Tag (pMxH), which will help the 
proteins to chelate to Nickel ions in the column.
iii. The supernatant after sonication was loaded on to the Nickel 
Chelating Sepharose column, which was charged with 100 mM 
Nickel sulphate and equilibrated with buffer 0.1 M Tris-HCI pH 8.0, 
0.15 M NaCI.
iv. Variable concentration of Imidazole (10 -  250 mM) was used to 
elute the protein.
v. The elution buffer used was 0.1 M Tris-HCI pH 8.0, 0.15 M NaCI 
and (10 - 250 mM) imidazole.
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vi. After elution the fractions were run on a SDS-PAGE system to 
check for the right molecular weight bands.
vii. The right fractions were then transferred into a dialysis membrane 
and dialysed against buffer containing 0.1 M Tris-HCI and 0.15 M 
NaCI overnight at 4° C.
viii. Nickel from chelating sepharose column was washed with 20 mM 
EDTA and equilbrated and stored in 20 % ethanol. The column was 
recharged with 100 mM Nickel sulphate and equilibrated with buffer 
(0.1 M Tris-HCI pH 8.0, 0.15 M NaCI) prior to next run.
ix. A sample gel picture is shown in Fig 2.12.
,-nJA/U
11 12 13 14 15 16 17 18 19 20
-
• * "
Fig 2.12 SDS-PAGE after affinity chromatography 1. Lane 1 and 11 are the 
BenchMark™ Protein Ladder (Invitrogen). Lane 1: crude sample (soluble) 
after sonication; lane 2-5: flow through from load; lanes 6-20: eluants with 
different concentration of imidazole. Lanes 6-8: 10 mM imidazole; Lanes 9-12: 
20 mM imidazole; Lanes 13-19: 40 mM imidazole; Lane 20: 100 mM 
imidazole. The advantage of using higher pH buffer like Tris-HCI over Hepes 
buffer is that the associated impurities at 100 mM imidazole eluant is avoided 
by eluting the protein of interest at a low concentration of imidazole. Also LHn 














Next day the dialysed sample was collected in a duran or a falcon 
tube and UV absorbance at 280 nm was measured. The reference 
sample used was the dialysis buffer.
Based on the difference in absorbance at 310 nm and 274 nm the 
protein concentration was calculated using the formula “protein 
concentraion (mg/ml) = difference between UV absorbance at 274 
nm and at 310 nm, divided by path length of the cell'’.
100 pi of the sample were taken in an eppendorf before Factor Xa 
treatment to run on SDS-PAGE system next day.
Factor Xa (bought from NEB) was added to the sample (1 unit of 
Factor Xa per 0.1 mg of the protein) and incubated at 25° C for 24 
hours in order to achieve full cleavage of N-terminal His-Tag or 
MBP-Tag or His-MBP-tag from the protein and also to separate the 
light chain and heavy chain by cleaving the Factor Xa linker site 
between the two chains.
After Factor Xa treatment, 100 pi of the sample were taken to run 
on an SDS-PAGE system.
2 samples were prepared, one before and one after the treatment of 
Factor Xa.
Each sample contained 25 pi of protein sample, 25 pi of 4x Nu 
Page loading buffer and was made up to 100 pi with water.
2 more samples were prepared in the same way as in step xiv with 
25 pi of protein sample, 25 pi of 4x Nu Page loading buffer, 10 pi of 
1 M DTT and were made up to 100 pi with water.
All the four samples were run on an SDS-PAGE system.
A sample gel picture is shown in Fig 2.13
76
I Dal 2 3 4 5
L 6 0 —
. o o -
S O * "
M
Fig 2.13 SDS-PAGE: LHC-EGF after Factor Xa treatment and reduced with 
1M DTT. Lane 1 is the BenchMark™ Protein Ladder (Invitrogen). Lanes 2 and 
4: before and after Factor Xa treatment; lanes 3 and 5: before and after Factor 
Xa treatment plus 1M DTT. The bands observed at a molecular weight of 
-150 kDa is the MBP-LHn fusion (lanes 2 and 3). Lane 4 is only LHn after 
cleaving the N-terminal MBP tag. The cleaved MBP is observed as a strong 
band at around -45 kDa molecular weight (lane 4 and 5). In lane 5 the band 
observed at around -50 kDa molecular weight is the light and translocation 
domain of LHn.
Affinity Chromatography 2 :
xx. This step helped in getting more pure protein. After the cleavage of
the His-Tag the protein of interest was in the flow through.
xxi. The fractions were run on SDS-PAGE system for verification.
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xxii. The buffer used was 0.1 M Tris-HCI pH 8.0, 0.15 M NaCI.
xxiii. A sample gel picture is shown in Fig 2.14.
10 .11 12 13 14 15cDa
Fig 2.14 SDS-PAGE: LHC-EGF after second affinity chromatography. Lane 1 
is the BenchMark™ Protein Ladder (Invitrogen). Lanes 2-15 is flow through. 
LHC-EGF is seen as a high molecular weight protein (-100 kDa) at the right 
place on the SDS-PAGE (lanes 5-15).
Size-Exclusion Chromatography:
xxiv. This was the final step in purification of recLHn fragments to get 
more pure protein.
xxv. Superdex 200 30/100 Pharmacia ready-made prepacked column or 
Superdex 200 column was used.
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xxvi. The buffer used was 0.1 M Tris-HCI pH 8.0, 0.15 M NaCI.
xxvii. After this step the samples were concentrated using 50 kDa 
molecular weight cut-off concentrators (Vivascience).
xxviii. A sample gel after size-exclusion chromatography is shown in Fig 
2.15.
k D a
Fig 2.15 A sample SDS-PAGE gel picture after size-exclusion 
chromatography. Lane 1 is the BenchMark™ Protein Ladder (Invitrogen). 
Lanes 2-4: concentrated sample after second affinity chromatography; lanes
6-9: after size-exclusion chromatography. The very strong band observed at 
-50 kDa is the associated E.coli protein that could not be avoided during 
affinity chromatography. After size-exclusion chromatography the very strong 
band at 50 kDa (lanes 2-4) is mostly avoided (lanes 6-9). The band at 
molecular weight -100 kDa (lanes 6-9) is the LHn.
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Final protein concentration and purity assessment:
The protein sample eluted from size-exclusion chromatography was 
concentrated to desired volume using the 50 kDa molecular weight cutt-off 
conenctrators. The concentration of the protein sample was measured using 
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Fig 2.16b BCA assay for pHx-LHA-S877. The mean absorbance for pHx- 
LHA-S877 sample was 0.875. Substituting this value for y  in the equation on 
the graph the concentration of pHx-LHA-S877 was calculated to be 1.35 
mg/ml. This was from a litre culture and about ~83 % pure.
For purity assessment the final concentrated sample was loaded on a SDS- 
PAGE at very high concentration (~0.1 -  0.2 mg/ml). The gel was stained and 
scanned using the densitometer and a graph was tabulated (Table 2.5) to 
determine the percentage of purity of the sample (Fig 2.24).
Table 2.3 Densitometer reading for pHMx-LHA-S877 after size-exclusion 
chromatography and concentration. The sensitivity was increased to 2 instead 
of 4, which was used as standard for LHn fragments. This increase in 
sensitivity accounted for the extra bands observed on the gel (Fig 2.17) and is 
used for other LHn fragments purity assessment.
LINE- 1 Line Width: 3 Pixels
Max.
Sensitivity Noise Min. Area Area Auto Noise Baseline
2 0.001 Yes Automatic
Peak# Area Height Percent Apex(pixel) Separation
1 1.698 0.126 84.487 55 W
2 0.029 0.007 1.443 99 BB
3 0.17 0.018 8.433 131 BB
4 0.069 0.01 3.423 195 BV
5 0.045 0.007 2.214 212 BB
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Pixel: 301 O.D.: 0.011
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Fig 2.17 Optical density of the stained protein sample -  output from the 
densitometer.
Summary
All the following eleven constructs were cloned, expressed and purification 
trials were performed.








pHx-LHA-S877 100 0 .3 -3 .0 83.0
pHx-LHA-K625A 100 <1.0 <60.0








92 Could not estimate the 
quantity because of poor 





pMxH-LCC 50 <1.0 <80
pHMx-LHC-His-Tag
(pHMx-LHC-HT)
100 35 .0 -40 .0 94.0









Success has been achieved in obtaining the first X-ray diffraction pattern for 
LHA-S877 and LHC-EGF. Many different constructs (section 2.8) of LHn 
fragments were cloned, expressed and purified in order to find a successful 
candidate for structural studies. Surface engineering of LHn/A, truncation 
product of LHn/A, light chain of serotype C, and LHC-EGF fusion protein were 
also expressed and purified. The other constructs were not produced on a 
large scale and screened for crystallisation because of initial success with 
LHA-S877 and LHC-EGF. The yield of LHA-S877 is very low ranging between 
0.8 mg -  3 mg per litre culture with a purity of ~80%. Hence, LHA-S877 were 
expressed in large quantities and purified for crystallisation trials with a purity 
of -93 %. LHC-EGF is a very well expressed protein about 30 mg -  40 mg per 
litre culture. Due to time constraint and funding the work is stopped at this 
stage. Further optimisation of crystallisation conditions LHA-S877, LHC-EGF 
and LHC-HT is required.
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2.9 First Crystal Structure of Recombinant Botulinum Neurotoxin B
Clostridium botulinum B protein receptors in cell-mediated endocytosis are 
synaptotagmin I and II. The receptors bind to a conserved region in the He 
domain that corresponds to the sialic acid binding site on tetanus toxin. Based 
on the extensive research performed by our collaborators Dr. Thomas Binz 
and Dr. Andreas Rummers laboratory, Institut fur Biochemie, Hannover, 
Germany, attempts were made to co-crystallise/soak the synaptotagmin 
peptide with botulinum neurotoxin B.
Here we report the first crystal structure of recombinant botulinum neurotoxin 
B (hereafter referred as BotB) at 1.9 A resolution (Thiyagarajan et al., 
unpublished results).
2.9.1 Materials and Methods
Recombinant BotB was prepared (Rummel et al. 2004) and supplied for 
crystallisation trials at very high concentration of ~10-13 mg/ml. 
Synaptotagmin II (hereafter referred as Syt2) fragments were mixed to BotB 
at different ratios to ensure the peptide is bound to BotB. The protein was 
stored in buffer 50 mM Tris-HCI pH 8.0, 150 mM NaCI, and 2.5 mM CaCL.
2.9.2 Co-crystallisation of BotB -  Synaptotagmin Complex
Attempts were made to co-crystal I ise BotB-Syt2 complex. Different ratios of 
Syt2 to BotB were mixed and several hundreds of crystallisation trials were 
screened. Soaks of Syt2 to the obtained BotB crystals were also tried and 
several dataset has been collected at Synchrotron Radiation Source at 
Daresbury Laboratory. Attempts to obtain a BotB-Syt2 complex data were 
unsuccessful. Recombinant whole length (~1310 aa) BotB was crystallised 
completely in a different condition those used and reported for crystallisation
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of BotBs from native source (Swaminathan and Eswaramoorthy 2000), where 
ammonium sulphate was used as precipitant. BotB crystallised in P2-i space 
group using the condition 8-10 % PEG 6000, 0.1-0.25 M Mes buffer at pH 5.5- 
6.5.
Crystallisation screens were attempted using hanging drop vapour diffusion 
technique in 24-well Linbrow plates (Molecular Dimensions Ltd, UK). The drop 
ratio of protein (BotB-Syt2 mixture) to mother liquor is maintained to be 1:1. 
Different ratios of protein to mother liquor were also tried. Standard structure 
screens I and II, and PEG/lon screen from Molecular Dimensions Ltd, 
Ammonium sulphate grid screen from Hampton Research, were initially 
screened. The drops were equilibrated with 500-1000 pi of mother liquor in 
the reservoir and incubated at 16°C. The drops were routinely monitored for 
any crystallogenesis to appear in the drop after every 24 hours from initial 
setup.
Observations made directed towards pH range from 5.0 to 7.0 to be screened 
further using PEG as precipitant. Different PEGs from range 1000 to 12000 
were tried. Buffers tried were Bis-Tris, Mes, Sodium cacodylate, and Na 
citrate. All chemicals were purchased from Sigma (UK), PEGs from Fluka 
(UK). High-quality grade HPLC water is used to prepare all the solutions. 
Crystalloids were observed after a week in drops containing PEG 6000 in 
buffer Mes pH 6.0. Varying the precipitant concentration against constant 
ionic strength resulted in thin plate crystals, needles, and crystalloids and of 
not use for X-ray diffraction studies. Attempts made in varying the 
concentration of the buffer resulted in better crystals. These crystals diffracted 
to 2.6 A resolution at the SRS, Daresbury.
Optimisation was carried to grow better crystals in order to obtain higher 
resolution data. Several additives like nickel chloride, N-acetyl galactosamine, 
N-acetyl glucosamine, alcohols such as MPD (2-methyl-2,4-pentanediol), 
ethylene glycol, glucose, sucrose were tried. Detergents were also used as 
additives in crystallisation. BotB-Syt2 were mixed at equal proportions and
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screened for crystallisation using the same condition 8-10 % PEG 6000, 0.1- 
0.25 M Mes pH 5.5-6.5 whilst detergents were used as additives this time. 
Parallelopiped single crystals grew after a week in a drop containing 1:1:0.3 
ratio of protein to mother liquor to detergent equilibrated against the reservoir 
solution 8-10 % PEG 6000, 0.1-0.25 M Mes pH 5.5-6.5. A single crystal grown 
using sucrose monolaurate detergent as additive diffracted to 1.9 A resolution 
and data were collected at PX station 14.2, SRS, Daresbury. The toxin 
crystals lose their diffraction quality though not the shape after three weeks 
from they are formed. Hence, the crystals need to be freshly grown prior to 
data collection.
Fig 2.18 Different crystals of BotB: a) 12 % PEG 6000, 0.1 M Mes pH 6.0; b) 
10 % PEG 6000, 0.1 M Mes pH 6.0; c) 8% PEG 6000, 0.15 M Mes pH 6.0; d) 
10 % PEG 6000, 0.25 M Mes pH 6.0; e) 10 % PEG 6000, 0.25 M Mes pH 6.0, 
sucrose monolaurate; f) 10% PEG 6000, 0.25 M Mes pH 6.0, 2mM NAG.
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2.9.3 Single Crystal Data Collection and Processing
X-ray diffraction data were collected at ~100K at SRS, Daresbury Laboratory 
on PX station 14.2 (A=0.978 A). Diffraction images were recorded on an 
ADSC Quantum 4 Detector. The crystal was cryoprotected in 25 % Glycerol in 
mother liquor prior to data collection. Diffraction data were collected with an 
oscillation range of 1°.
HKL2000 (Otwinowski and Minor 1997a) suite was used for X-ray data 
processing and scaling. The data were indexed, processed and scaled in
primitive monoclinic space group with cell dimensions a=76.24 A, b= 122.79
A, c= 95.19 A, a= 90°, (3=112.4°, y=90°. Calculation of Matthew’s coefficient
gave a value of Vm=2.96 with 1 molecule per asymmetric unit. Initial indexing 
resulted in a space ambiguity between C-centred monoclinic and primitive 
monoclinic. There was doubling of two cell dimensions in C-centred 
monoclinic space group compared to primitive monoclinic. This could be 
because of the presence of pseudocentering in C-centered space group. 
Initially data were processed in C-centred monoclinic space group because of 
excitement that the BotB-Syt2 existence might have given a new crystal form. 
But after molecular replacement solution, and electron density calculation, 
and analysis using graphics disproved the choice of selection of C-centred 
monoclinic system. The data was reprocessed in primitive monoclinic space 
group P 2\.
2.10 Results and discussion 
Molecular Replacement
Initial phases were obtained using molecular replacement method from the
phases of 1EPW with protein atoms only. The program AmoRe or Molrep
(Navaza 1994; Vagin and Teplyakov 1997) was used for molecular
replacement method. Phases were refined using Crystallographic and NMR
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bright
suite (CNS) with a test set of reflections kept aside to calculate the Rfree 
(Brunger 1992; Brunger et al. 1998). Crystallographic data collection statistics 
are given in Table 2.5.
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Fig 2.19 X-ray diffraction image of BotB. The resolutions circles are shown in 
red. The numbers on the resolution circles refers to the resolution of X-rays in 
angstrom units.
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Table 2.5 Crystallographic data collection and refinement statistics
BotB
Resolution (A) 50-1.9






(outermost shell) (%) 52.3




Number of solvent molecules 882
RMS deviation from ideality
in bond lengths (A) 0.008
in angles (°) 1.4





aRSymm = ^hki^i\l{hkl) - <\>(hkl)\rLhkiZh{hkl) where <l> is the averaged intensity 
of the / observations of reflection hkl.
bRcryst = S|Fo| - |Fc|/2|Fo| where Fo and Fc are the observed and calculated 
structure factor amplitudes, respectively.
cRfree is equal to Rcryst for a randomly selected 5% subset of reflections not 
used in the refinement.
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Structure Analysis and Validation
For the first time the recombinant BotB was crystallised with the full length of 
the toxin with the linker region remain intact (Fig 2.20) and not proteolytically 
cleaved between light and heavy chain domains. The disulphide bridge 
between residues Cys 441 and Cys 450 is clearly mapped in the electron 
density. The N-terminal portion of the molecule was less disordered but most 
of the backbone and sidechain positions could be fitted into the electron 
density map. Phases for the C-terminal residues from 1290 are highly 
disordered and could not be modelled into the electron density map.
Fig 2.20 2F0-FC (in blue contoured at 1.0 a) and F0-Fc (in green contoured at 
3.0 a) electron density maps for the linker region is shown. The average 
thermal factor for atoms in this loop is around 55.
After the first round of refinement Zn2+ ion was inserted at the active site with 
the help of 2F0-FC and Fo-Fc weighted SIGMAA maps in its coordination 
sphere (Fig 2.21). The translocation belt partially occludes the Zn2+ binding 
site similar to 1EPW (Swaminathan and Eswaramoorthy 2000). After careful 




the hinge between translocation domain and the catalytic domain (Fig 2.23. 
Though crystallisation conditions did not include any Ca2+, it might have been 
carried through during the purification process of the protein. Two glycerol 
molecules and one sulphate ion were also found on the surface of the toxin. 
Glycerol molecules are found one at the C-terminal domain interacting with 
main chain atoms of residues G1108, N1109 and 11244 and one near the light 
chain interacting with ND2 of N134, whereas the sulphate molecule was found 
near the hinge between light chain and translocation domain.
Role of zinc ion:
Extensive research has been done and reported on the role of Zn2+ ion in 
botulinum neurotoxins (Vallee and Auld 1990a; b; Montecucco and Schiavo 
1993). Zn2+ ion is very important for the catalytic activity of the toxin, though 
substitution with other metal ions (Eswaramoorthy et al. 2004) could render 
some catalytic activity to the enzyme. It is thought that the presence of Zn2+ 
ion could be for both structural and functional stability of the molecule, but 
reports have shown that the presence of zinc ion is only catalytic and has no 
influence on the conformation of the light chain (Breidenbach and Brunger 
2004; Eswaramoorthy et al. 2004; Agarwal et al. 2005).
Role o f calcium ion in botulinum neurotoxins:
Presence of Ca2+ ion in BotB participates in intracellular translocation of the 
toxin (Eswaramoorthy et al. 2004). The calcium ion coordinates with three 
light chain residues P281, I284 and D289, and one residue N488 from the 
translocation domain belt region (Table 2.6) (Fig 2.22). There is also a 
coordinating water molecule present at the calcium bound site. Presence of 
calcium ion in any other serotype of botulinum neurotoxins is not reported yet. 
The presence of calcium ion is common among zinc proteases like 
thermolysin (Colman et al. 1972; Matthews et al. 1974), adamalysin II (Gomis-
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Ruth et al. 1994), and matrix metalloproteases. The presence of calcium ions 
is thought to play a role in structural stability of the enzyme. About 20-30 % of 
botulinum neurotoxins light chain is restored by metal substituent like Mg, Mn 
or Ca (Ahmed and Smith 2000).
H234'
Fig 2.21 Zn2+ site at the catalytic centre. Zinc ion -  go/d; water -  cyan; 
coordinating residues in ball-and-stick model -  grey and standard atom 
colours for atoms belonging to the protein residues. 2F0-Fc electron density 
map contoured at 1.0 a.
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Fig 2.22 Ca2+ ion between translocation domain and catalytic domain. 
Calcium ion -  green: water -  cyan: coordinating residues in ball-and-stick 
model -  grey and standard atom colours for atoms belonging to the protein 
residues. 2F0-FC electron density map contoured at 1.0 a.
Analysis of BotB structure with available botulinum B structure (PDB: 1EPW) 
(Swaminathan and Eswaramoorthy 2000) superpose with a root-mean square 
deviation (rmsd) value of 0.62 A for C-alpha atoms. The catalytic domain (LC) 
(light chain) comprises of a mixture of a-helices and (3-strand secondary 
structures with the coordinating metal ligand Zn2+ ion at the active site (Fig 
2.21). The active site is located in a deep cleft partially occluded by the 
translocation belt of the translocation domain. The Zn2+ coordination and 
conserved residues around this site is well pronounced in all CNTs.
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Table 2.6 Coordination distance for Zn2+ and Ca2+ ions in BotB
Metal Ion Amino Acid Side 
Chain
Distance (A)
His 234 NE2 2.10
His 238 NE2 2.23
Zn2+ water 2.42
Glu 272 OE1 2.33
Glu 272 OE2 2.42
Pro 281 0 2.56
lie 284 0 2.44
Ca2+
water 2.45
Asp 289 OD1 2.50
Asp 289 OD2 2.56
Asn 488 ND2 2.40
The translocation domain (H im) has its unique structural feature with two long 
amphipathic a-helices that run anti-parallel to each other (Fig 2.23). Cys 450 
from translocation domain forms an intramolecular disulphide bridge with Cys 
441 of light chain. The translocation belt from E487 to F542 spans the 
catalytic domain partially occluding the zinc site inaccessible to the substrate 
and thereby rendering the toxin inactive. The translocation domain is believed 
to form ion-conducting channels in artificial membranes (Donovan and 
Middlebrook 1986; Blaustein et al. 1987; Shone et al. 1987; Schmid et al. 
1993). BotB reported here is from a recombinant source and is not 
proteolytically cleaved between light chain and heavy chain and the linker 




Fig 2.23 Ribbon diagram representation of whole toxin recombinant BotB. 
Light chain (LC) -  cyan; translocation domain HN -  brown; Binding domain -  
He: HCn -  green; HCc -  violet; Zinc -  blue; Calcium -  green; sulphate and 
glycerol molecules are shown as ball-and-stick models
The binding domain (Hc) has two sub-domains mainly of (3-sheet topology 
linked by a single a-helix. The C-terminal residues play a very important role 
in receptor binding. Mutation studies of the C-terminal residues resulted in 
loss of activity of the toxin or intoxification into the neuronal cells resulting in 
failure of binding of the toxin to the cell membrane. The superposition of the 
binding domain of BotB with 1F31 in complex with sialyllactose reveals 
glycerol molecule of BotB bound near the ganglioside binding region of the 




Fig 2.24 Superposition of binding domains of BotB -  cyan and 1F31 -  
magenta (Swaminathan and Eswaramoorthy 2000). Corresponding ligands 
are shown in similar colour with respect to the molecule they belong to.
Analysis of structural data confirms that more than 85.5 % of residues in most 
favourable region, 12.6 % in additionally allowed region, and 1.3 % in 
generously allowed region of the Ramachandran plot (Fig 2.25), compared to 
only 0.6 % of residues in disallowed region. This is because of poor or 
disordered electron density map where the regions could not be fixed.
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Fig 2.25 Main chain torsion angle plot (Ramachandran plot) for BotB
Conclusion
Several attempts to co-crystal I ise BotB-Syt2 complex in equi- and/or variable 
proportional mixtures were unsuccessful. This could be because of 
crystallographic artifact where the toxin molecules pack in a particular fashion. 
Thus the complexes in solution might have fallen apart under crystallographic 
conditions. A glycerol molecule was found at the substrate-binding site of 
botulinum neurotoxin B (Fig 2.24). It is evident that if synaptotagmin II were 
bound at the ganglioside binding site of BotB there would not be any/enough 
space left for the glycerol molecule to be seen at the site. This explains the 
fact that, though the BotB-Syt2 is found as complex in solution but not in 
crystals.
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One way to overcome this problem is to express and purify the protein and 
peptide as a fusion protein using recombinant methods. The peptide could be 
linked to the C-terminal of the protein by a short flexible linker 
molecule/peptide of length ~10 - 20 amino acids, thus allowing the ~65 amino 
acid length synaptotagmin II to span freely over the ganglioside binding 
domain. Other approach could be to purify and crystallise only the binding 
domain of BotB with synaptotagmin II. This might help the complex to be 
crystallised without any fusion approach.
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Chapter 3
Crystal Structures of E r y t h r i n a  c r i s t a g a l l i  




Lectins are carbohydrate-binding proteins (glycoprotein) of molecular weight 
ranging between 60 kDa - 110 kDa and are often classified based on 
saccharide specificity. Lectins can be found in plants, animals, bacteria and 
viruses and are involved in biological recognition functions. Lectins have one 
or more binding sites per subunit, which can reversibly bind to specific sugar 
segments through hydrogen bonds and van der Waals interactions (Ashford 
et al. 1991). The term lectin (legere - Latin verb for to select) was coined by 
Boyd to emphasise the ability of some hemagglutinins to discriminate blood 
cells within the ABO blood group system (Boyd and Reguera 1949). Some of 
the lectins were found to be toxic to humans (Vasconcelos and Oliveira 2004) 
and animals. In general, nausea, bloating, vomiting and diarrhea characterize 
the oral acute toxicity of lectins on humans exposed to them. Plant lectins are 
subdivided into four major classes: Merolectins, Hololectins, Chimerolectins 
and Superlectins (Van Damme et al. 1998).
Depending on the specificity towards a given monosaccharide and/or 
oligosaccharide the lectins will selectively bind to one of these sugars (D- 
mannose/D-glucose, A/-acetyl-D-galactosamine, A/-acetyl-D-glucosamine, L- 
fucose and N-acetylneuraminic acid) that are typical constituents of eukaryotic 
cell surfaces (Ashford et al. 1987). One of the most important features of 
plant lectins is their defense mechanism against proteolysis and stable over a 
wide pH range. Legume lectins serve as a model system to study the 
molecular basis of protein-carbohydrate specificity. The specificity, high 
stability over a wide pH range, etc. has attracted lectins towards therapeutics 
as a fusion protein with botulinum neurotoxin in the treatment of chronic 
pain(Chaddock et al. 2004).
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3.1 Erythrina cristagalli lectin
Fig 3.1 Erythrina cristagalli
Erythrina cristagalli is an ornamental plant commonly called as ‘coral tree’ (Fig 
3.1). The lectin from this plant is specific for galactose and A/-acetyl- 
galactosamine (Iglesias et al. 1982; Ashford et al. 1991). Erythrina cristagalli 
lectin (ECL) exhibits similar affinity to fucosyllactose and fucosyllactosamine, 
whereas other members show higher affinity for fucosyllactose (Teneberg et 
al. 1994; Moreno et al. 1997; Srinivas et al. 2001; Svensson et al. 2002). in 
vitro studies on ECL has shown that they have hemagglutinating activity and 
is mitogenic for human T lymphocytes (Iglesias et al. 1982; De Boeck et al. 
1985; Harris et al. 1987). Recently, a conjugate comprising a catalytically 
active derivative of Clostridium botulinum neurotoxin A (LHN/A) coupled to 
ECL has been used to selectively target nociceptive afferents (Duggan et al. 
2002; Chaddock et al. 2004).
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3.2 Medical application of ECL
ECL due to its high carbohydrate specificity has drawn the attention of 
pharmaceutics and researchers to use this as a drug delivery vehicle for use 
in gene therapy to cure SCID (Severe Combined Immunodeficiency Disease) 
and in the treatment of chronic pain (Chaddock et al. 2004).
3.3 Materials and methods
Crystallisation, data collection and structure solution of ECL were performed 
by Dr. Kathryn Turton. Model building, structure validation and analysis were 
performed by me.
Protein purification and crystallisation: Native ECL (a?ECL) was purchased 
from Sigma (UK). The purified recombinant ECL (recECL) was supplied from 
Dr. John Chaddock’s laboratory. The DNA extracted from E.cristagalli leaves 
were amplified by polymerase chain reaction (PCR) and cloned into vector 
pMTL1015. The clone was transformed into E.coli BL21 (DE3) cells and 
expressed (OD6oo = 30) in an 8-litre fermentation culture at 37° C. The protein 
was solubilized from inclusion bodies, subsequently refolded and purified on 
an immobilized lactose matrix. After extensive washing, recECL was eluted by 
the addition of 0.3M lactose (Stancombe et al. 2003).
Crystallisation was achieved using the vapour diffusion method (hanging 
drops) at 16°C and crystals were observed within 3-4 weeks. The 
crystallisation conditions used is given in Table 3.1.
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2pl of protein solution, 2jj.I of 
mother liquor plus 0.4pil of 100 
mM lactose solution.
800pl of mother liquor (70% 




2pl protein and 2ptl of mother 
liquor.
800pl of mother liquor (17% 
PEG 3350, 0.3M sodium 




2pl protein and 2jlxI of mother 
liquor.
800pl of mother liquor (20% 
PEG 3350 and 0.2M 
imidazole).
X-ray data collection and structure determination: X-ray diffraction data were 
collected at 100K using the Synchrotron radiation source at Daresbury, UK on 
station PX14.1 (wavelength 1.483A). Raw data images for /?ECL were indexed 
and integrated using DENZO (Otwinowski and Minor 1997a), then scaled with 
SCALEPACK (Otwinowski and Minor 1997a). X-ray images collected for the 
recECL crystals were processed and scaled using HKL2000 (Otwinowski and 
Minor 1997a) (Table 3.1).
Phase determination: Initial phases were obtained by the molecular
replacement method using the program AMoRe (Navaza 1994). For nECL,
the crystal structure of ECorL at 1.95A resolution (PDB code 1AX1) (Elgavish
and Shaanan 1998) was used as an initial model with the nine non-conserved
residues mutated to alanine and all waters, ligands and metal ions removed.
Refinement was performed using the CNS suite of programs (Brunger et al.
1998). After one round of refinement, the crystallographic R factor (RCrySt)
dropped to 29.59% (Rfree 32.38%, based on 5% of reflections omitted from the
refinement). Calculated phases from the refined structure were used to
determine |F0|-|FC| and 2|F0|-|FC| electron density maps. Careful examination
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of the |F0|-|FC| map allowed mutation of the non-conserved residues back to 
their native side-chains and the addition of calcium and manganese ions to 
the model. HEPES and lactose were built into electron density of each 
protomer, with parameter and topology files from the HICUP server (Kleywegt 
and Jones 1998a). Similarly glycosylated sugars (3 in molecule A and 6 in 
molecule B, part of the heptasaccharide bound to Asn113) were modelled into 
the |F0|-|FC| electron density map, riding on Asn113 residue. Repeated rounds 
of refinement and model building were carried out to improve the model. After 
several rounds of refinement, water molecules were added to the structure if 
there were peaks in the |F0|-|FC| electron density maps with heights greater 
than 3a at hydrogen bond forming distances from the appropriate atoms. 
2|F0|-|FC| maps were also used to check the consistency in peaks. Water 
molecules with a temperature factor of >60A2 were excluded from subsequent 
refinement steps.
Subsequent solution of recECL structures was achieved using the refined 
coordinates of /7ECL (at 2.0A resolution) as a search model. Model building 
and refinement procedures were undertaken as described for /?ECL. For 
recECL in space group P1, apart from the lactose molecule glycerol was 
modelled into the carbohydrate-combining site. The program PROCHECK 
(Laskowski et al. 1993) was used to assess the quality of each structure after 
the final round of refinement. Analysis of the Ramachandran plot for each 
structure revealed that over 99% of residues were located in allowed regions 
of the plot. All the figures were prepared with the program Bobscript (Esnouf 
1997a).
3.4 ECL structure
ECL is active in its dimeric state and adopts the conserved jelly-roll topology
(Fig 3.2), characteristics of other legume lectins. It forms non-canonical
dimers via the handshake motif which was first observed in Erythrina
corallodendron lectin (EcorL) (Shaanan et al. 1991), a close homolog (96%) to
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ECL. In the EcorL structure the A/-linked heptasaccharide is bound to Asn17, 
which is at the dimer interface and forms the handshake motif. The 
carbohydrate moiety from the two molecules in the asymmetric unit interacts 
by means of hydrogen bonds and is believed to be responsible for the non- 
canonical dimer formation. But, in the native structure of ECL, the protomers 
are A/-glycosylated at Asn113 and the carbohydrate moiety is on the opposite 
side of the dimer interface (Fig 3.2).
The ECL structure comprises a six-stranded back p-sheet, a short five- 
membered p-sheet, and a set of loops connecting the three sheets. Each 
protomer contains one Ca2+ and Mn2+ ion (Fig 3.3), both of which are required 
for carbohydrate binding activity (Emmerich et al. 1994). These ions help in 
maintaining the correct spatial orientation of the carbohydrate binding 
residues (Derewenda et al. 1989). The interaction of these ions within the 
molecule in the asymmetric unit is listed in Table 3.2. A cis-peptide between 
residues Ala88 and Asn89 holds the side chain of Asn89 in the correct 
orientation for carbohydrate binding (Svensson et al. 2002).
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Table 3.2 -  Contacts between ECL and metal ions
Metal
Ion




Asp 136 OD2 2.40
Asp129 OD2 2.53




Asp 129 CG 2.9
Asp 129 OD1 2.6












Asp 129 CG 3.2
Asp 129 OD2 2.2
Asp 136 CG 3.1












Fig 3.2 The structure of ECL dimer. Protomers of ECL associate together
back-to-back to form non-canonical dimers via the “handshake motif as was 
first observed for ECorL. The dimer structure is stabilized by two hydrogen 
bonds and a series of contacts between side chains in four strands of the flat, 
six-stranded p-sheet. The protomers are tilted with respect to one another 
such that the N- and C-termini play no part in the dimer interface. Each 
protomer adopts the conserved jelly-roll fold characteristic of legume lectins. 
The A/-linked carbohydrate (yellow) (on Asn113), lactose (gold) bound at the 
combining site and HEPES (green) molecules (from the crystallisation 
medium) are shown. The manganese (dark green) and calcium (grey) ions 









Fig 3.3 Ca2+ (yellow) and Mn2+ (green) ions interaction with the molecule is 
shown. Water molecules are shown in blue colour and labelled as ‘w’
3.5 Results and discussion
Native ECL (nECL) - 1UZY: nECL co-crystal I ized with lactose in space group 
P65, with two molecules per crystallographic asymmetric unit and 67% of the 
crystal volume occupied by solvent. The final model (dimer) at 2.0A resolution 
(Rcryst 18.97%, Rfree 20.92%) contains 477 amino acids, two calcium and 
manganese ions, two lactose molecules, four GlcNAc residues, two fucose 
residues, one xylose, two mannose residues, four HEPES molecules and 456 
water molecules (Table 3.3). The estimated Luzzati coordinate error is 0.22A. 
Analysis of the Ramachandran plot revealed that the side-chains of over 99% 
of the amino acids have allowed or additional allowed conformations. The 
side-chains of Tyr106 in each molecule adopt generously allowed 
conformations. The first three residues of the heptasaccharide bound to 
Asn113 were modelled into the electron density in one of the two protein 
molecules in the asymmetric unit, while electron density for six of the seven 
sugar residues was observed in the other.
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Recombinant ECL (recECL): recECL (1UZZ) crystallized in triclinic form, with 
four molecules per unit cell (49% of the crystal volume occupied by the 
solvent). The final model at 2.13A resolution (Rcryst 19.1%, Rfree 24.1%) 
contains 958 amino acids (molecule A, 1-239; molecule B, 1-239; molecule C, 
1-240 and molecule D, 1-240), four calcium and manganese ions, three 
glycerol molecules and 879 water molecules (Table 3.3). The Luzzati 
coordinate error is 0.23A and the average B factor for protein atoms is 
24.52A2. |F0|-|FC| electron density in the combining site of three protomers was 
identified as glycerol, which had been included in the cryoprotectant solution 
used during data collection. A single residue, Tyr106, in only one of the four 
protomers is located in a generously allowed region of the Ramachandran 
plot. Possible alternative conformations were observed in the electron density 
map for the side-chains of Ser120, but not in all of the molecules in the unit 
cell.
recECL (1V00) was also co-crystal I ized with lactose in space group P2i, with 
four molecules per asymmetric unit (49% solvent). The final model at 1.7A 
resolution (Rcryst 17.79%, Rfree 20.31%) contains 959 amino acids, four lactose 
molecules, four calcium and manganese ions and 1119 water molecules 
(Table 3.3). The Luzzati coordinate error is 0.20A and the average B factor for 
protein atoms is 19.99A2. Five amino acid residues are located in generously 
allowed regions of the Ramachandran plot -  Tyr106 from each protomer and 
Asp221 from one of the four protein molecules. Several side-chains were 
observed to have potential alternative conformations (Met95, Asp161, Leu180 
and His234) but not in all of the protomers.
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Table 3.3 - Crystallographic data processing and refinement statistics
nECL recECL recECL
DATA PROCESSING:
Space group P65 P1 P2i
Cell dimensions (A) a = 134.02 a = 55.28 a = 54.90
b= 134.02 b = 55.37 b = 167.23
c = 81.64 c = 86.93 c = 55.13
a = p = 90° a = 86.23° p n -< ii CD O o
oOCMII>- P = 75.37° P = 97.09°
Resolution (A) 2.00
y = 82.13° 
2.13 1.70
Reflections measured 414,754 399,699 1,021,770
Unique reflections 56,451 55,200 108,695
Completeness (%) 99.7 93.1 94.1
in the outermost shell 99.9 86.1 77.3
l/(al) 18.44 10.93 28.05
in the outermost shell 6.22 5.29 5.26
Rsymm 0.070 0.077 0.058
REFINEMENT:
Rcryst ( % ) 18.97 19.10 17.79
Rfree ( % ) 20.92 24.10 20.31
Average B factor (A2) 28.84 24.52 19.99
Wilson 23.1 25.60 19.20
RMSD from ideality: 
Bonds (A) 0.005 0.009 0.006
Bond angles (deg) 1.44 1.47 1.49
Dihedrals (deg) 25.32 26.15 26.10
Impropers (deg) 0.78 0.91 0.78
Rsymm = E/»w£, - <\>{hkf)\IT,hkiLfr{hkf) where <l> is the averaged intensity of the /'
observations of reflection hkl.
Rcryst = Z|F0| - |FC|/Z|F0| where F0 and Fc are the observed and calculated structure factor 
amplitudes, respectively.





The A/-linked glycosylation is observed at Asn113 of the nECL. The C1 atom 
of NAG951 forms a covalent bond (1.45A) with ND2 atom of Asn113. The 
carbohydrate moiety has direct interaction with 16 water molecules. The 
stereo image of the heptasaccharide bound to the nECL is shown in the Fig






Fig 3.4 Details of the surrounding residues for the hexasaccharide at the 
glycosylation site (Asn113). In the crystal lattice, the N-linked carbohydrate 
makes indirect interaction with the combining site through water-mediated 
interaction. Water molecule is shown as small blue spheres.
Lactose binding site
The lactose molecule is bound to the nECL by means of hydrogen bonds. The 
lactose forms six hydrogen bonds with residues Asn113, Gly103, Asp89, 
Ala218, Glu219 and has direct interaction with nine water molecules. Fig 3.5 
shows the stereo image of the lactose interaction with the molecule in the 
asymmetric unit. Fig 3.7 shows the well defined electron density for the 
lactose molecule.
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Fig 3.5 Binding of lactose to ECL. Residues involved in carbohydrate binding 
are: Leu86, Asp89, Gly107, Asn133, Ala218 and Gln219. Water molecules 
are shown as small blue spheres.
Fig 3.6 Electron density for the N-linked heptasaccharide (There is not 
enough density to build the seventh sugar unit). 2F0-FC electron density map 
contoured at 1.0 a.
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A218 A®219
Fig 3.7 Electron density (blue) showing the disaccharide molecule and for the 
backbone and residues (light grey) surrounding the disaccharide. 2F0-FC 
electron density map contoured at 1.0 a.
The native ECL (nECL) superimposes with EcorL with an overall rmsd (root 
mean square deviation) of 0.37A for Ca atoms (238) and 0.39A for main chain 
atoms (952) (Fig 3.8). The nECL superimpose with recombinant ECL 
(recECL) with an rmsd of 0.26A for Ca atoms (238).
Comparison of the two structural models indicated that there are no significant
differences between the crystal structures of native and recombinant forms of
ECL and, thus, confirming that recECL adopts native-like structure (rmsd =
0.26A). The A/-linked oligosaccharide bound to nECL is covalently bound to
Asn113, which is part of the loop structure located between strands p5 and
p6. This residue is the only possible site of attachment for A/-linked
glycosylation in the 241-amino acid sequence of ECL. In one of the two
protein molecules in the asymmetric unit, there was enough electron density
to model six of the seven sugar residues bound to Asn113 (Fig 3.6). The
modelled hexasaccharide has the profile: aD-Man-(1-»3)-[p-D-Xyl-(1-»2)]-p-
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D-Man-(3-D-GlcNAc-(1—>4)-[a-L-Fuc(1-»3)]-D-GlcNAc and does not make 
contacts with any other parts of the lectin protomer to which it is bound, 
although it might communicate with the lactose moiety bound in the combining 
site of a symmetry-related molecule through water mediated interactions.
Fig 3.8 Superposition of monomers of nECL (1UZY) (native ECL in blue) with 
EcorL (1LTE in red) for Ca-atoms (rmsd=0.37A).
Influence of glycosylation on the quaternary structure
In nECL the oligosaccharide is bound covalently to Asn113 (present study) 
and not to Asn17 (Shaanan et al. 1991). It was believed that the binding of 
the heptasaccharide to Asn17 prevents the formation of the canonical dimer 
(Shaanan et al. 1991). But, the recECL, which is unglycosylated at positions 
Asn17 or Asn113, also forms dimers back-to-back via the “handshake” motif. 
This mode of oligomerisation seems to be energetically more favourable than 
any other quaternary forms (Prabu et al. 1999; Elgavish and Shaanan 2001; 
Manoj and Suguna 2001; Srinivas et al. 2001). Thus, the presence or 
absence of A/-linked glycosylation do not influence the mode of dimerisation in
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ECL and suggests that factors intrinsic to the primary structure of the lectin 
dictate its quaternary structure.
Conclusion
The observation on A/-glycosylation of ECL by Shaanan et al (1991), 
Svensson et al (2002) and the present analysis tells that the A/-glycosylation is 
independent of the dimer formation. The lectins carbohydrate specificity and 
the inferences invite the researchers to plan mutational studies on ECL, 




Crystal Structure of Bovine Pancreatic 




Proteins are the final products of transcriptome of an organism and play a 
variety of role in a living system. Proteins that catalyse the biochemical 
reactions such as breakdown or make-up of bio-products in an organism are 
classified as enzymes. Enzymes are named after the function they perform 
with a suffix -ase in their name. The catalytic rate of reaction of an enzyme is 
several fold orders of magnitude than in the absence of it. Enzymes are very 
specific to the reactions they catalyse. Because of their specificity to the 
substrate and higher activity, they are molecules of interest to industry, drug 
companies, and biological research.
Ribonucleases (RNases) are special class of enzymes that are RNA specific 
and possess the ribonucleolytic activity. Ribonucleases catalyse the process 
of breakdown of any free RNA. There are many different ribonucleases 
classified and grouped as endo- and exo- ribonucleases depending on their 
mechanism of function. RNases play a variety of roles in a biological system 
and are molecules of interest in current research because of special clinical 
properties like cytotoxicity. Cytotoxicity of RNases depends on their catalytic 
activity, which is cytosolic RNA degradation thereby damping the protein 
production factory. This cytotoxic property of RNases has made them a 
molecule of interest for use in cancer therapeutics. Retargeting RNases in 
fusion with cell binding proteins to invade tumour cells have been reported in 
many researched papers (e.g. angiogenin in fusion with anti-CD22 (Newton et 
al. 2001) / CD30 (Huhn et al. 2001) / Epidermal Growth Factor (EGF) (Yoon et 
al. 1999), RNase A in fusion with EGF (Jinno et al. 1996)).
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4.1 Bovine Pancreatic Ribonuclease A
Bovine pancreatic ribonuclease A (RNase A) is the first secretory endo- 
ribonuclease to be identified and isolated from bovine pancreas (Kunitz 1940). 
RNase A is relatively a small molecule of 124 amino acids and of molecular 
weight 14 kDa. It is a molecule of interest to biochemists and structural 
biologists for many years because of its remarkable biochemical and 
biophysical properties, for example four disulphide bonds (Fig 4.1a), which is 
unusual for a molecule of such a small size. RNase A catalyses the 
degradation of RNA by cleaving the phosphodiester bonds in RNA in the 3 ’ - 
5 ’ direction resulting in 2’, 3 ’ -  cyclic phosphates (Fig 4.1b) (D’Alessio and 
Riordan 1997; Raines 1998).
RNase A has been well characterised in terms of its stability, structure 
(Wyckoff et al. 1967a; Wyckoff et al. 1967b; Wyckoff et al. 1970; Richards et 
al. 1972), mechanism of action, protein folding, etc., and is used as a model 
system by biologists because of its ease of availability (the cow pancreas) and 
purification. RNase A is a ‘Nobel Molecule’ for it being Stanford Moore, 
William Stein and Christian Anfinsen shared the Nobel Prize in chemistry in 
the year 1972 for their work relating the chemical structure and catalytic 
activity of the enzyme’s active site. In 1984, Bruce Merrifield was awarded the 
Nobel Prize for the development of novel method of chemical synthesis on a 
solid matrix. Bruce Merrifield used RNase A as a model system like others. 
Ribonucleases are molecules of scientific interest in the past few decades and 
now, for their properties other than the degradation of RNA, like cytotoxicity, 
anti-viral and anti-bacterial agents, angiogenic property, etc.
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Fig 4.1a Three-dimensional structure of Ribonuclease A (PDB: 1W40) {grey) 
and disulphide bonds (red) are shown. Residues involved in disulphide 
bridges are C40-C95; C26-C84; C58-C110; C65-C72.
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Fig 4.1b Schematic representation of formation of 2 -3 ’ cyclic phosphate. AH 
and B stands for acid and base respectively. Bent arrows shows the 
movement of electrons.
4.1.1 Active Site o f RNase A
Structural features of RNase A
RNase A is a kidney shaped molecule (Fig 4.1a) with three cr-helices, seven 
/3-strands stabilised by four disulphide bonds - two at each pole of the 
molecule. RNase A is pyrimidine specific and catalyses the cleavage of 
phosphodiester bonds in RNA molecules. The active site of RNase A 
constitutes the phosphate binding sites PO, P1 & P2, and the base binding 
sites B1 & B2 (Fig 4.2a). A schematic representation (Pares et al. 1991) of the 
active site is given on the right side of Fig 4.2a. The PO site consist only one 
residue K66. The P1 site, which is the primary active site, consists of residues 
Q11, H12, K41 and H119. H12 and H119 act as acid-base catalysts in 
breakdown of the phosphodiester bonds (Fig 4.1b) and form a catalytic triad 
with K41. The P2 site consists of residue K7. The B1 site where the 
pyrimidine base binds consists of residues T45, F120 and S123. The B2 site 

















Fig 4.2a Catalytic sites of RNase A: The phosphate binding sites (PO, P1, P2) 
and the base binding sites (B1, B2) are represented in different colours. R1, 
R2 are the ribose units.
The RNA binds between the active sites in the 5-3 ’ direction and the 
phosphate backbone is cleaved in the 3-5 ’ direction between the sugars R1 
and R2 (Fig 4.2a). The active site is positively charged (Fig 4.2b) thus 
favouring the negatively charged RNA to bind strongly. Several mutation 
works on the active site residues confirmed the importance of residues (Smith 
and Raines 2006) H12, T45 (Jenkins et al. 2005), K41 and H119 involved in 
the catalytic activity of the enzyme. The PO and P2 sites in addition to the P1 
site also binds the phosphates of the bases and plays a very important role in 
the substrate specificity and catalysis (McPherson et al. 1986; Birdsall and 
McPherson 1992; Fontecilla-Camps et al. 1994; Fisher et al. 1998a; Fisher et 
al. 1998b; Nogues et al. 1998; Cuchillo et al. 2002).
121
Fig 4.2b GRASP surface charge representation of ribonuclease A showing 
that the active site is highly concentrated with basic residues resulting in high 
positive charge. Picture adapted from Ribonucleases, Part A, Methods in 
Enzymology, 341, pp-194.
4.1.2 RNase A Superfamily
Ribonuclease A and its homologues together constitute Ribonuclease A 
superfamily, so far reported only in vertebrates (Beintema and Neuteboom 
1983; Beintema et al. 1988; Beintema 1998; Rosenberg 1998; Zhang et al. 
2000; Rosenberg et al. 2001; Cho et al. 2005; Dyer and Rosenberg 2006). 
Ribonucleases were also reported in prokaryotes (Oda et al. 1991; 
Katayanagi et al. 1993) and plants (Abel and Glund 1986; Konieczny et al. 
1991; Taylor et al. 1993).
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EDN (RNase 2) I P . . . . . . . . . . . P Q P T M Q W F E M M . .
ECP (RNase 3) MGPKLLESRLCLLLLLGLVLMLASCLSQTPSQWPAIQEIKN NANLQCWVEMQRINRFRRTC
RNase A —  - . . . . . .   KETAAAKFEF QB MDSSTSMSSSNYCWQMMKSRHLTKDRCE
ANG (RNase 5) — . . . . *. . AQDDYRYIHFL1QE YDAKPKG-RNDEYCFNMMKNR-RLTRPC K
Onconase —  - . . . . . . . — . . XDWLTFQlfpN- --TRDVDCDNILSTN--LFHCgp
SQiPLLTTFANWNVCGNPNMTCPSNR 67 
ILFIFLHTSFMAVGVCGNPSGLCSDNI 90 
PI IFVHBSLADVQAVCSQKNVACKMGQ 6 9 
5RIIFIHGNKNDIKAICEDRNGQPYRGD 69 
0 1FIYSRPEPVKAICKG-  IIASKNV 57
* * * *♦ * ** .
EDN (RNase 2) TRKHCHHSOSQVPLIHCNLTTPSPQmSHCRYAQTPANMFYIVACDNRDQRRDPPQYPWP 
ECP (RNase 3) SR-KCHNSSSRVRITVCNITSRRRTPYTQCRYQPRRSLEYYTVACNPRTPQ-DSPMYPWP
RNase A TN- -CYQSYSTMSITDCRETGSSK- -YPHCAYKTTQAKKHIIVACEG. . . . NPYVP
ANG (RNase 5) LR— - ISKSEFQITICKHKGGSS- - RPPCRYGATEDSRVIVVGCENG. . . . . -LPD






Fig 4.3b Multiple sequence alignment of ribonucleases of RNase A superfamily. Conserved catalytic residues are boxed in red.
RNase A Onconase EDN
Fig 4.3a Structural similarity between RNases of RNase A superfamily. RNase A (PDB: 1W40); Onconase (PDB: 10NC); EDN (PDB: 
1HI2); Angiogenin (PDB: 1H52); ECP (PDB: 1QMT)
Angiogenin
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RNase A superfamily consists of ribonucleases of pancreatic origin and 
eosinophil origin. The ribonucleases belonging to RNase A superfamily share 
similar fold/topology in their tertiary structure, fold architecture and overall 
sequence similarity, and identity at their catalytic site residues (Fig 4.3a,b). 
Some of RNase A homologues are Angiogenin (RNase 5), Eosinophil-Derived 
Neurotoxin (EDN/RNase 2), Eosinophil Cationic Protein (ECP/RNase 3), 
Onconase (Frog ribonuclease), and RNase 4. RNase A shares an overall 
sequence similarity of 44%, 46%, 54%, and 46% with onconase, EDN, 
angiogenin, and ECP respectively.
Brief description of RNase A homologues
Angiogenin: A ~14 kDa protein and a member of RNase A superfamily with 
unusual biological properties (Strydom et al. 1985; Bicknell and Vallee 1988; 
1989; Bond et al. 1993; Jimi et al. 1995; Soncin et al. 1997; Hu et al. 2000) 
and exhibit weak ribonucleolytic activity (Shapiro et al. 1986; St Clair et al.
1988). Angiogenin shares an overall sequence identity of 40% to RNase A 
(Strydom et al. 1985) and involved in blood vessel formation and tumour cell 
growth. Angiogenin is found in different species including human, mouse, 
bovine, zebrafish (Pizzo et al. 2006), and many others. High-level expression 
of recombinant human angiogenin and murine angiogenin in Escherichia coli 
has been reported (Holloway et al. 2001). Structural studies on bovine, human 
and murine angiogenin were also reported highlighting the catalytic residues 
involved in substrate binding, key residues mediating cell surface binding of 
angiogenin, and residues involved in molecular recognition (Shapiro et al. 
1989; Shapiro and Vallee 1989; Acharya et al. 1992; Acharya et al. 1994; 
Russo et al. 1994; Acharya et al. 1995; Leonidas et al. 1999a; Jardine et al. 
2001; Leonidas et al. 2001b; Holloway et al. 2004; Holloway et al. 2005).
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ECP: Eosinophil Cationic Protein is ~15.5 kDa in molecular weight and found 
in eosinophil granules. It shares an overall sequence identity of 33% with 
RNase A. Structural characterisation of ECP revealed the formation of 
catalytic triad similar to RNase A (Boix et al. 1999) and thus ECP possesses 
ribonucleolytic activity which is responsible for its functional properties. In vitro 
studies of ECP has shown that they function as anti-bacterial (Lehrer et al.
1989) and anti-viral (Harrison et al. 1999) agents. Neurotoxic effect of ECP 
results in Gordon phenomenon, a muscular paralysis. Other properties of 
ECP are helminthotoxicity (Hamann et a!. 1990), and cytotoxicity (Young et al. 
1986). Reports have shown that ECP might be involved in degranulation of 
eosinophils (Klion and Nutman 2004; Lee and Lee 2005).
EDN: Eosinophil-Derived Neurotoxin is a major constituent of human 
eosinophil leukocytes sharing an overall sequence identity of 34% to RNase A 
(Durack et al. 1981; Gleich et al. 1986) and -70% sequence similarity to ECP 
weighing about 18.4 kDa. Similar to ECP EDN also possesses neurotoxicity 
effect leading to the loss of Purkinje cells in cerebellum. The catalytic centre 
of EDN is structurally characterised and reported confirming that 
ribonucleolytic property is important for its neurotoxicity (Leonidas et al. 
2001a). Recent investigations have shown that EDN acts as a chemotactic 
agent in dendritic cells (Yang et al. 2003; Oppenheim and Yang 2005).
Onconase: Onconase is an amphibian ribonuclease from Rana pipiens (Ardelt 
et al. 1991). It shares an overall sequence identity of 32% to RNase A. The 
protein possesses anti-tumour activity, which makes it a molecule of 
clinical/therapeutic interest and is in phase I I/I 11 clinical trials in the treatment 
of unresectable malignant mesothelioma (UMM) and Non-Small Cell Lung 
Cancer (NSCLC) (http://www.alfacell.com/).
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4.2 Inhibitors of Ribonucleases
The digestion of cellular RNA by RNases leads to RNA degradation. If this 
process is allowed to continue there will be no protein production in the cell 
and all RNases might become cytotoxic resulting in cell death (Vescia et al. 
1980; Wu et al. 1993; Leland et al. 1998; Suzuki et al. 1999). Nature has 
found a way to inhibit the ribonucleolytic activity of the RNases. Similar to 
RNases capturing free RNA molecules, ribonuclease inhibitors captures free 
RNases and makes them inactive.
4.2.1 Natural Inhibitor of Ribonucleases -  Ribonuclease Inhibitor (Rl)
The natural ribonuclease inhibitor (Rl) is ~50 kDa molecular weight Leucine- 
rich repeat (LRR) protein. Rl is a horseshoe shaped molecule (Fig 4.4) inner 
and outer diameter of ~21 A and ~67 A respectively. It consists of 16 /3- 
strands and 16 a-helices connected by /3/a and a//3 loops. It exhibits very high 
affinity in the order of fM (femto molar) (Bicknell and Vallee 1989; Shapiro and 
Vallee 1991; Bond et al. 1993; Hofsteenge et al. 1998) range to RNases of 
RNase A superfamily, exception includes onconase where the affinity is of the 
order of >1 pM (micro molar) (Boix et al. 1996). Rl has been isolated and 
purified from human (hRI), rat (rRI), and porcine (pRI) sources. Crystal 
structures of Rl on its own (Kobe and Deisenhofer 1993) and in complex with 
RNase A (Kobe and Deisenhofer 1995; 1996), angiogenin (Papageorgiou et 
al. 1997), and EDN (Iyer et al. 2005) have been reported.
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Fig 4.4 Ribbon diagram representation of Ribonuclease Inhibitor (Rl) (PDB: 
2BNH). (Kobe and Deisenhofer 1993)
4.2.2 Small Molecule Inhibitors of Ribonuclease A
In order to understand the mechanism of action of an enzyme one needs to 
understand the chemical nature and structure of the active site. Initial studies 
were done by subjecting/treating the enzyme under suitable chemical 
conditions (Weil and Seibles 1955; Barnard and Stein 1959; Gundlach et al. 
1959). Small molecule inhibitor studies on RNase A as a model system will 
aid us in understanding the mechanism of function of the enzyme in living 
organism and the key residues involved in ribonucleolytic activity. Most of the 
RNase A inhibitors are potent inhibitors of EDN, Angiogenin, and RNase 4 
(Russo and Shapiro 1999; Russo et al. 2001). Thus an effective inhibitor of 
RNase A could be tested on its homologues.
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An inhibitor could be competitive or non-competitive. Competitive inhibition 
depends solely on the affinity of the inhibitor to the enzyme’s active site 
resulting in an inactive enzyme-inhibitor complex. The strength of inhibition is 
defined by K, values, which is a quantitative measure of inhibitor strength. 
Small molecule binding studies to RNase A has revealed the important 
catalytic residues of the enzyme and also that these molecules could be used 
as inhibitors of RNase A activity. Some of the small molecule inhibitors are 
bromoacetate (Barnard and Stein 1959), iodoacetate (Gundlach et al. 1959), 
2’-deoxyuridine 3’-phosphate (Walz 1971), and arabinonucleotides (Pollard 
and Nagyvary 1973).
Several small molecule inhibitors of RNase A have been reported from our 
laboratory. A few of them are listed in the Table 4.1.
Table 4.1
Inhibitor Ki References
ppA-3'-p -0.24 mM (Leonidas et al. 1997; Russo et al. 
1997)
ppA-2'-p -0.52 mM (Leonidas et al. 1997; Russo et al. 
1997)
dUppA-3'-p -11.3 pM (Jardine et al. 2001)
pdUppA-3'-p -0.027 pM (Leonidas et al. 1999b; Russo and 
Shapiro 1999)
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4.3 RNase A in Complex with Non-natural 3 -nucleotides
RNA based inhibitor design for RNase A has been the most common method 
used (Russo et al. 1997; Russo and Shapiro 1999; Russo et al. 2001). Any 
approach had the ribose/deoxy-ribose sugar unit as a standard (Stowell et al. 
1995).
Does the ribose/deoxy-ribose molecuie play an important role in binding of the 
inhibitor to RNase A?
Here, we report the synthesis and structural details of the complexes with 
RNase A of two 3’-nucleotides containing nonnatural furanose rings: 
2’-fluoro-2’-deoxyuridine 3’-phosphate and arabinouridine 3’-phosphate.
4.3.1 MATERIALS AND METHODS
4.3.1.1 Synthesis of Non-natural 3’-nucleotides
The synthesis of non-natural 3’-nucleotides and kinetic studies were done in 
our collaborator Professor Ronald Raines Laboratory, University of 
Wisconsin-Madison, USA, and reported along with the structural complex of 
RNase A (Jenkins et al. 2005).
4.3.1.2 Crystallisation, Data Collection and Structure Solution
Bovine pancreatic RNase A was obtained from Sigma. RNase A crystals were 
grown using the vapour diffusion technique as described in ref (Leonidas et al. 
1997); they belong to the space group C2, with two molecules per asymmetric
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unit. Crystals of the complexes were obtained by soaking the RNase A 
crystals in 20 mM sodium citrate, pH 5.5, and 25% PEG 4000, 50 mM dUMP, 
1 mM araUMP, 12.5 mM d llFMP for 45, 60 and 75 minutes respectively prior 
to data collection. Diffraction data for the three complexes were collected at 
100 K (the reservoir buffer with 30% PEG 4000 was used as cryoprotectant) 
on stations PX 14.1 and PX 9.6 from a single crystal at the Synchrotron 
Radiation Source, Daresbury, UK using an ADSC Quantum 4 CCD detector. 
All diffraction images were integrated using HKL2000 (Otwinowski and Minor 
1997b). Initial phases were obtained using the structure of free RNase A 
(Leonidas et al. 1997) as a starting model. The refinement was carried out 
using the CNS suite (Brunger et al. 1998) and the model building was carried 
out using O (Jones et al. 1991). Initial model building and refinement was 
carried out without the inhibitor. In each data set, a set of reflections was kept 
aside for Rfree calculation (Brunger 1992). The inhibitor and water molecules 
were modelled using both the 2Fo-Fc and Fo-Fc SIGMAA weighted maps. 
The topology and parameter files for the inhibitors were either generated 
manually and/or using the Hic-up server (Kleywegt and Jones 1998b) 
http://alpha2.bmc.uu.se/hicup/. All three structures have good geometry, and 
more than 87% of the protein residues are in the most favourable region of 
Ramachandran plot. All structural diagrams were prepared using the program 
Bobscript (Esnouf 1997b).
4.3.1.3 Determination of K, values for the inhibitors
The values of K\ for the four 3’-nucleotides were measured by their ability to 
inhibit the cleavage of the fluorogenic substrate 6-FAM-dArU(dA)2-TAMRA 
by wild-type RNase A and its T45G variant (Kelemen et al. 1999), and are 
listed in Table 4.2. All four 3’-nucleotides were potent inhibitors of the wild- 
type enzyme, whereas inhibition of T45G RNase A was less pronounced—by 
up to three orders-of-magnitude. Phosphoryl group pKa values were 
determined by 31P NMR spectroscopy. Inhibition was determined in MES- 
NaOH buffer, pH 6.0, containing NaCI (50 mM).
131
Table 4.2 Values of pKa and K\ for 3’-nucleotides. Chemical 









3’-UMP 5.84 ± 0.05 39 ±2 89 ±9
dUMP 6.29 ± 0.07 18 ± 3 >1700
d llFMP 5.89 ±0.10 5.5 ±0.7 181 ± 15
araUMP 5.85 ± 0.06 6 ± 1 >1000
4.4 X-ray crystallographic structures of dUMP, d l lFMP and arallMP 
complexes
The 3D structures of the three complexes of RNase A were determined at 
high resolution using X-ray crystallography (Table 4.3). The binding of the 
nucleotides at the catalytic site were clear in all three complexes (except for 
molecule B in arallMP complex due to severe cracking of crystals while 
soaking) as observed from the electron density maps (Fig 4.5b). The complex 
structures superimpose well with that of the RNase A native structure with an 
rms deviation in the range of 0.52A. The interactions made by dUMP, dUFMP 
and araUMP complexes are similar (Fig. 4.6a-c, Table 4.6a-c) and the 
nucleotides predominantly bind at sites Pi, Bi and P2. The predominant 
hydrogen bonds were observed between uracil and Thr45; the 3’-R- 
phosphate with the side chains of Gln11, His12, Lys41, and His119, and the 
main chain of Phe120 at the catalytic site (Fig 4.6d).
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Tab le  4.3: C rysta llograph ic  sta tistics
RNase A complex dUMP araUMP dUpMP
Resolution (A) 50-1.69 50-1.60 50-1.68
(Outermost shell) (A) 1.75-1.69 1.66-1.60 1.74-1.68
Reflections measured 184,596 455,952 239,956
Unique reflections 27,984 30,191 27,669
p  a r'symm 0.093 0.086 0.047
(Outermost shell) 0.122 0.517 0.086
Completeness
(outermost shell) (%) 91.4 (94.2) 89.9 (88.5) 94.8 (87.6)
<l/al> (outermost shell) 9.83 10.3 5.18
p b r\c ryst 0.22 0.23 0.21
(Outermost shell) 0.21 0.50 0.29
KfreeC 0.23 0.25 0.24
(Outermost shell) 0.27 0.54 0.33
Number of solvent
molecules 291 203 310
RMS deviation from ideality
in bond lengths (A) 0.010 0.005 0.004
in angles (°) 1.5 1.2 1.3
Average B factor (A2) 18.4 27.92 14.95
aRSymm = Z/,Z,-|l(Ai) - \i(h)/lhl\\i(h), where, \\(h) and I(h) are the ith and the mean 
measurements of the intensity of reflection h.
bRoyst = ^ |F 0 - Fc|/Ia,F0, where, F0 and Fc are the observed and calculated 
structure factors amplitudes of reflection h, respectively. 
cRfree is equal to Rcryst for a randomly selected 5% subset of reflections not 
used in the refinement (Brunger 1992).
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Fig 4.6d A ribbon diagram and ball-and-stick representation of active sites 
(P1, B1) of RNase A-dUMP complex. The dUMP is shown as ball-and-stick 
(gold) model with the well-defined electron density around it. 2F0-FC electron 
density map contoured at 1.0 a.
In all three complexes the uridine binds in an anti conformation, and its ribose 
adopts a C3’-exo, C2’-endo and 04 ’-endo pucker in dUMP, araUMP and 
dUpMP respectively (Altona and Sundaralingam 1972) (Table 4.7). The 
difference in conformation of the ribose moiety can be attributed to the 
presence of additional atom/s attached at C2’ position (-OFI group in araUMP 
and fluorine atom in the dUpMP complex) (Fig. 4.7b, Fig 4.8a-b).
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Fig 4.6a Details of the interactions at the catalytic site of 
RNase A molecule and dUMP. Water molecules are 
represented by small spheres. Hydrogen bonds are indicated 
by dashed lines.
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Table 4.6a Potential hydrogen bonds of dUMP with RNase A
dUMP atom RNase A residue Distance (A)
N3 Thr45 - 0G1 2.82
01P His12 - NE2 2.83
01P Phe120- N 3.01
03P His119 - ND1 2.54
02 ’ His12 - NE2 2.86
02 ’ Gln11 - NE2 2.83




02 ’ water 3.29
04 ’ water 3.04
Fig 4.6b Details of the interactions at the catalytic site of 
RNase A molecule and araUMP. Water molecules are 
represented by small spheres. Hydrogen bonds are indicated 
by dashed lines.
Table 4.6b Potential hydrogen bonds of araUMP with RNase A
araUMP atom RNase A residue Distance (A)
02 Thr45 - N 2.87
N3 Thr45 - 0G1 2.70
03P His12 - NE2 2.71
03P Phe120- N 2.89
01P Gln11 -NE2 2.95
02 ’ His119 - ND1 2.66
03 ’ Lys41 - NZ 3.11





02 ’ water 2.84








Fig 4.6c Details of the interactions at the catalytic site of 
RNase A molecule and dUFMP. Water molecules are 
represented by small spheres. Hydrogen bonds are indicated 
by dashed lines.
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Table 4.6c Potential hydrogen bonds of dUFMP with RNase A
dUFMP atom RNase A residue Distance (A)
02 Thr45 - N 2.61
N3 Thr45 - 0G1 2.71
01P Gln11 -NE2 2.93
03P His12 - NE2 2.75
02 ’ His119 - ND1 2.50
02 ’ Phe120 - N 3.09










Fig 4.5a Chemical structure of non-natural 3’-nucleotides
araUMP
Fig 4.5b Portions of the electron density maps (2Fo-Fc) for dUMP, araUMP 
and dUpMP respectively. 2F0-FC electron density map contoured at 1.0 o.
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0 1 P - -
S conformation N conformation
C2'-endo-C3'-exo C2'-exo-C3'-endc
Fig 4.7a S and N conformation of nucleosides.
Fig 4.7b Stereo representation of dUMP-dark green; araUMP- blue; dUpMP- 
gold.
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Table 4.7: Torsion angles statistics for dUMP, araUMP, dUFMP when bound 
to RNase A
RNase A molecule dUMP araUMP dU MP
Backbone torsion angles
0 5 ’-C5’-C4’-C3’ (y) 86.3 (+sc) 73.0 (+sc) 62.9 (+sc)
C5’-C4’-C3’-03 ’ (5) 123.4 (+ac) 94.8 (+ac) 66.7 (+sc)
C5’-C4,-C3’-C2’ -99.7 -145.7 -158.4
C4’-C3’-C2’-02 ’ — 93.0 -134.1
Glycosyl torsion angles
0 4 ’-C1’-N1-C2 (x’) -107.3 (anti) -156.2 (anti) 176.0 (anti)
Pseudorotation angles
C4’-04’-Cr-C2’ (u0) 2.5 -40.3 -27.9
0 4 ’-C1’-C2’-C3’ (ui) 23.6 50.9 16.3
Cr-C2’-C3’-C4’ (u2) -41.8 -39.3 -2.8
C2’-C3’-C4’-04 ’ (u3) 42.7 17.9 -16.0
C3’-C4’-04’-C r (u4) -28.9 15.2 28.8
Phase 201 144 96
C3’-exo C2’-endo 0 4 ’-endo
C2’-C3’-03 ’-P 85.1 89.2 103.5
C4’-C3’-03 ’-P -147.4 (-ac) -158.4 (+ap) -121.8 (-ac)
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4.5 Results and Discussion
3’-Nucleotides with a nonnatural furanose ring can have a greater affinity for 
wild-type RNase A than do 3’-nucleotides with a ribose or deoxyribose ring. 
The K\ values increase in the order: dUFMP » araUMP < dUMP < 3’-UMP 
(Table 1). 3’-Nucleotides with a dianionic phosphoryl group is known to be 
more potent inhibitors of RNase A than those with a monoanionic phosphoryl 
group (Russo et al. 2001). The difference in pKa values between dUMP and 
the other three nucleoside 3’-phosphates is approximately 0.4 pKa units 
(Table 4.2). Likewise, the K\ value of dUMP with wild-type RNase A is 
approximately 3-fold higher than those of dUFMP and araUMP. 3-UMP has a 
higher K\ value with wild-type RNase A than would be expected based on its 
pKa. This weaker binding could arise from the 2’-OH group participating in 
more unfavourable interactions with the enzyme than do the smaller 2’-groups 
(F or H) of the other 3’-nucleotides.
These unfavourable interactions could be reinforced by the tight interaction 
between the uracil base and Thr45, and by a slight preference for the C3’- 
endo (N) conformation of 3’-UMP in solution (Davies and Danyluk 1975) (Fig 
4.7a). It is interesting to note that in the structure of the crystalline RNase 
A-3’-UMP complex (Leonidas et al. 2003), the ribose ring is found in the C2’- 
endo rather than the C3’-endo conformation. Like 3’-UMP, dUFMP resides in 
the C3’-endo conformation (Antonov et al. 1976), but has a smaller fluoro 
group in its 2’-position. dUMP (Guschlbauer and Jankowski 1980) and 
araUMP (Chwang and Sundaralingam 1973; Venkateswarlu and Ferguson 
1999) are predominantly in the C2’-endo (S) conformation and both have 
hydrogens where 3-UMP has a larger hydroxyl group. The weaker binding of 
3’-UMP compared to dUMP and araUMP lends supports the hypothesis that 
ground-state destabilization contributes to the catalytic prowess of RNase A 
(Kelemen et al. 2000).
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Another possible reason for the K\ value of 3’-UMP being greater than those of 
the other 3’-nucleotides with wild-type RNase A is that the energetic penalty of 
desolvating the 2-OH group is higher than for any of the other 2’-substituents. 
The 2’ H and F of dUMP and dUFMP are more easily desolvated than is a 
hydroxyl group, due to their lack of ability form hydrogen bonds with water 
(Howard et al. 1996), and the 2’-arabino hydroxyl group of araUMP might not 
need to be desolvated for that 3’-nucleotide to bind to RNase A because it is 
oriented away from the active-site residues.
The binding of 3’-nucleotides by T45G RNase A follows a much different trend 
than does binding by the wild-type enzyme. The K\ values increase in the 
order: 3’-UMP < dUFMP «  araUMP,dUMP. 3’-UMP has half of the affinity for 
T45G RNase A than for the wild-type enzyme, whereas dUFMP has 3% of the 
affinity. The K\ values for dUMP and araUMP could not be measured, but 
were estimated to be £1.7 and £1 mM, respectively. The general decrease in 
binding between T45G RNase A and the inhibitors underlines the importance 
of the interaction between Thr45 and pyrimidine nucleobases in substrate 
binding (delCardayre and Raines 1994; 1995; Kelemen et al. 2000). The 
binding of 3’-nucleotides to T45G RNase A appears to be sensitive to the 
pucker of the furanose ring: 3’-UMP and dUFMP, which both reside in the 
C3’-endo conformation, bind with high micromolar affinities, whereas dUMP 
and araUMP, which both reside predominantly in the C2’-endo conformation, 
have at least millimolar affinities.
Without the anchoring presence of Thr45, the inhibitor can orient its furanose 
ring and phosphoryl group so as to optimise favourable contacts with active- 
site residues (Fig 4.8a-b). Thus, 3’-UMP could form a hydrogen bond between 
its 2’-OH and His12 or other active-site residues instead of participating in 
sterically unfavourable interactions. This putative hydrogen bond could be the 
source of the two-fold higher affinity of T45G RNase A for 3’-UMP than 
dUpMP. dUFMP cannot form a hydrogen bond with its 2’-fluoro substituent, but 
has a favourable conformation and pKa for binding to the active site at pH 6.
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Although araUMP has the same phosphoryl group pKa value as 3’-UMP and 
dUFMP, it has at least an order of magnitude lower affinity for T45G RNase A. 
Ring pucker could explain the lack of affinity between araUMP and T45G 
RNase A (compared to 3’-UMP and dUFMP). When the furanose ring is in the 
C2’-endo conformation, the nucleobase and phosphoryl group are placed in 
such a way that neither can interact optimally with active-site residues in the 
absence of the anchoring site provided by Thr45 in the wild-type enzyme. This 
lack of favourable interactions should be true for dUMP, as well. dUMP has 
the additional handicap of having a higher phosphoryl group pKa than the 
other 3’-nucleotides, with consequently diminished Coulombic interactions.
Fig 4.8a Anchoring of the phosphate moiety and base moiety at the active site 






Fig 4.8b Surface representation of active sites of RNase A-non-natural 3’- 
nucleotide complex. All the subsites are shown. The puckering of ribose 
moiety is shown in the right bottom quadrant of the figure.
Conclusion
Though the furanose ring puckering is specific to the T45G variant, it is less 
sensitive to wild-type RNase A (Table 4.2). The two most effective inhibitors of 
wild-type RNase A reported in this work are dUpMP and araUMP, which have 
different puckers in solution but indistinguishable K\ values. It has already 
been shown that in the context of a deoxyribose tetranucleotide ligand, a 2- 
fluoro-2’-deoxyuridine residue binds more weakly to RNase A than does a 
2’-deoxyuridine residue (Kelemen et al. 2000). Hence, we suggest that a most 
effective residue in creating new inhibitors of RNase A is arabinouridine, 
whose pKa value is close to dUMP and binds strongly to wild-type RNase A 
than dUMP. These compounds can be considered as the basis for the 
creation of new high-affinity ligands that could be used as effective drug 




Amino acid: Amino acids are building blocks o f proteins and there exist 20 
different natural amino acids. Each amino acid contains an amino- and 
carboxyl- group attached to alpha carbon.
Bioinformatics: A new field in biology uses information technology to aid in 
solving biological problems! Some of its functions are data mining and 
statistics, and development of algorithms for use in gene finding, sequence 
alignment, protein structure prediction, and genome assembly and 
organisation.
Bond angle: For any three points A, B and C in space, where A is bonded to 
B and B to C, then the angle between AB and BC is called bond angle.
Bond length: For any two points A and B that are bonded, the length 
between them is called bond length.
Chemical modification: To alter the chemical property of the molecule by 
substitution, deletion or addition of atoms.
Dihedral angle: Angle between any two planes is called dihedral angle. Also 
called as torsion angle.
Eukaryote: Eukaryotes are multicellular organisms. Some examples are 
plants, animals, and insects.
Genomics: A genome is a complete set of information about an organism at 
its DNA level. Genomics is the study of organisation of genomes to 
understand evolution, and characters of inheritance.
Microarray technology: A new high-throughput molecular biology technique 
to map and characterise genes, single nucleotide polymorphism (SNP) of 
genes, etc,.of a genome in a chip.
Nucleic acids: Nucleic acids are building blocks of deoxy-ribonucleic acid 
(DNA) and ribonucleic acid (RNA), the genetic material o f an organism. They 
are classified as purines and pyrimidines.
Peptide bond: The covalent bond between two amino acids is called peptide 
bond. The covalent bond is formed between carboxy- group of N-1th amino 
acid to amino- group of Nth amino acid. The geometry of the peptide bond is 
planar.
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Plasmid: Plasmids are circular DNA material of prokaryotes and some 
eukaryotes independent o f the chromosomal DNA of a cell. They are gene 
transfer vehicles between genomes. Genetically engineered plasmids are 
called as vectors and used extensively in research.
Prokaryote: Prokaryotes are single celled organisms, eg. bacteria.
Protein: Proteins are polymers of amino acids linked together by peptide 
bonds. They exist in different shape and structure and are synthesised in an 
organism. Proteins are vital for cellular functions.
Proteomics: The study of the proteome of an organism is called proteomics. 
High-throughput study involves structural characterisation o f different proteins 
on a large scale using robotics, pattern analysis of proteins in diseases, etc.
Virus: Viruses are particles that are capable of infecting prokaryotic or 
eukaryotic host cells. They are host dependent and cannot replicate on their 
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